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Abstract
Vascular type of Ehlers-Danlos Syndrome (vEDS) is an inherited cardiovascular disease affecting the
middle to large sized arteries, with an incidence rate of 1/5000. vEDS patients also show a significant
phenotype of easily bruised skin, indicating aberrant wound healing and injury repair ability. Over 70%
of the patients carry a glycine mutation located in their COL3A1 gene, which encodes the propeptide of
type III collagen. Mutations in glycine residues lead to a disruption in the assembly and maturation of
type III collagen. The goal and significance of the current study was to investigate the potential role of
COL3A1 haploinsufficiency in the development of vEDS and develop new potential therapies for vEDS
patients.
Carotid ligation was applied to the Col3a1+/- mouse as an injury model, and the results confirm that
Col3a1+/- mice have aberrant arterial injury repair. Arteries from the injured Col3a1+/-

mice showed

increased cell proliferation, inflammation, and neovessel formation. In vitro, fibroblasts explanted from
Col3a1+/- mice have persistent myofibroblast status after treatment with TGF-β1, which validates the in
vivo findings.
Finally, two treatments were tested on C o l 3 a 1 +/- mice after carotid ligation: bone marrow
transplantation and celiprolol. Transplantation of Col3a1+/+ bone marrow to Col3a1+/- mice corrects the
post-injury phenotypes, suggesting that bone marrow derived fibrocytes can be differentiated into
myofibroblasts and produce sufficient type III collagen for successful wound

healing. Celiprolol

treatment on the Col3a1+/- mice also corrects the wound healing impairment by decreasing inflammation
and cell proliferation. Therefore, this study validates a novel paradigm for vEDS that decreased supply of
mature type III collagen fibrils affects fibroblasts in arterial wound healing and also provides evidence
for bone marrow transplantation and celiprolol as potential new therapeutic approaches to the treatment
of vEDS patients.
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Introduction

1

1.1

What is vEDS?
Vascular type of Ehlers-Danlos Syndrome (EDS) is prominent by thin, translucent and easily bruised

skin; rupture of uterine, dissection of arterial or intestinal tissues and obvious facial appearance. These
defects affect connective tissues like skin and joints, causing abnormalities in uterus, colon and other
hollow organs1. vEDS is mostly resulted from the mutations in COL3A1 gene. Propeptide of type III
collagen is encoded by COL3A1 gene. vEDS patients develop aneurysms and dissection of arteries
throughout the body (Figure 1.1). Most patients with this syndrome develop when they are relatively
young, their medium to large sized arteries are usually accompanied with spontaneous arterial
complications. vEDS patients bruise easily and have spontaneous ecchymosis, which leads to chronic skin
discoloration from hemosiderin deposition most commonly on the shins and knees. In addition, they also
suffer from obstetric and gynecologic complications, including cervical insufficiency, vaginal tears and
lacerations. Gastrointestinal complications occur in up to 25% of patients, and the majority of these are
spontaneous rupture of the sigmoid colon2. The median life expectancy of vEDS patients is 40-50 years.
Death is likely due to the secondary to complications associated with vascular and hollow organ rupture 3.

2

Figure 1.1 Distribution of 132 vascular complications
Reprinted with permission from Elsevier [The spectrum, management and clinical outcome of
Ehlers-Danlos syndrome type IV: a 30-year experience. Oderich GS, Panneton JM, Bower TC, et
al. Journal of Vascular Surgery. 2005].

3

1.2

Diagnosis of vEDS
It is difficult to diagnose vEDS because many of the traits that vEDS patients have are subtle and

nonspecific. Easy bruising is the most frequent manifestation and is present in childhood 3. Other
phenotypes such as premature rupture of the arteries, membranes of different hollow organs, or recurrent
joint dislocation or subluxation. vEDS patients also have distinct facial features, like prominent and wideopen eyes, pinched nose, small and thin lips as well as lobeless ears. Early clinical diagnosis is
extraordinarily difficult without a diagnosis of familiar affection or major complication found in vascular
or intestinal tissues4.

1.3

Current therapeutic approaches and management to vEDS
vEDS is a rare genetic connective tissue disorder with life threatening complications that include

arterial dissection and ruptures, and intestinal and uterine ruptures, currently, there have been no
therapeutics with FDA-approval for vEDS patients in the United States, and physicians face the challenge
of establishing an effective preventative treatment plan for their patients5. One problem with assessing
treatment of vEDS patients is that the disease is relatively rare. Very few centers around the world have
significant experience in treating and managing these patients. In addition, given the extreme fragility of
the tissues, outcomes for interventions tend to be very poor, as even relatively simple diagnostic procedures
have a high rate of catastrophic complications. To possibly create a milder treatment, Pierre Boutouyrie et
al proposed a clinical trial for the drug, celiprolol, a cardio-selective β blocker (β-blocker) with β2 agonist
vasodilatory properties6. Because beta-blockers have historically been used for arterial diseases, it was
surmised that celiprolol could also help alleviate vEDS patients’ arterial dissection or rupture. Surgical
repair may decrease mortality caused by bowel rupture, arterial rupture, or uterus rupture. However, even
if the tissues are friable, repair procedure is very difficult, vascular surgeons must pay special attention to
these patients given their complicated vascular phenotypes and the complexities involved in repairing their
tissues.

4

1.4

Vascular Structure and Aorta
In vertebrate mammals, the arterial system is a network of extensive and dynamic vessels that

transport blood and deliver essential nutrients and oxygen to other parts of the entire body. Large arteries
are important for proper cardiac function because they serve as important reservoirs. These large arteries
enable the arterial tree to withstand great changes blood volume when there is barely pressure change7.
Although blood vessels are different in size, function and anatomy, they share similar basic elements to
form functional structure. Both arterial and muscular vessels are basically formed by three different layers,
the intima, the media, and the adventitia in comparison to the central lumen. There is a thin layer with the
lumen side of the intima which are lined by endothelial cells (ECs). ECs play a major role in development
of vasculatures as well as recruitment of smooth muscle cells (SMCs) to the vascular wall upon arterial
injury. The media is mainly composed of specialized vascular SMCs (vSMCs) and elastin. Under a variety
of circumstances, SMCs serve both to contracture and to produce components of extracellular matrix
(ECM). ECM mainly provide structures to resist forces generated by fluid flow and other mechanical
strength to arteries. The elastin is arranged in fenestrated sheets, and the collagen fibers, SMCs and ECM
float among the sheets. The adventitial layer is mainly composed of fibroblasts which also produce
adventitia components such as connective tissues. The larger aortic and vascular arteries also contain the
vasa vasorum which supply nutrients to the vessel walls themselves (Figure 1.2).

5

Figure 1.2 Schematic architecture of a representive medial in a muscular artery (left) and an elastic
artery (right).
The media of a muscular artery is bordered by the internal and external elastic laminae and contains
overlapping and concentrically-oriented smooth muscle cells. The media of an elastic artery instead
contains many elastic laminae alternating with muscular layers of smooth muscle cells that each
span the full thickness. The adventitia in a larger elastic artery also contains small blood vessels
(vasa vasorum) that nourish the outer layers of the wall. [Arteries, Smooth Muscle Cells, and
Genetic Causes of Thoracic Aortic Aneurysms. Chapter 12: Inflammatory Diseases of the Blood
Vessels, 2nd ed. Reid AJ and Milewicz DM1].
Quoted text and figure reprinted with minimal modification and permission from John Wiley and
Sons [Arteries, Smooth Muscle Cells, and Genetic Causes of 12 Thoracic Aortic Aneurysms.
Chapter 12: Inflammatory Diseases of the Blood Vessels, 2nd ed. Reid AJ and Milewicz DM1].
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1.5

Structure of collagen and their function
Fibroblasts are the major cell type which synthesize and secrete collagens. Among the 17 collagen

types, types I, III, IV, V and VI have the highest amount distributed in different tissues. Collagens I, III,
and V are assembled into fibrillary structure, with types I and III collagens playing a major role in
withstanding strength to the vessel wall. The fibrils are then formed according a self-assembly principle.
A protein monomer with the correct structure may aggregate with itself following a precise manner8. The
procollagens, also known as precursors, are first synthesized and then enzymatically cleaved to form the
corresponding collagens (Figure 1.3). Difference in the distribution of collagens I and III also occur in
different vascular vessel regions. In the ascending aorta’s media and adventitia, collagens I and III are
common while in the descending and medial layer, they are different distribution of type I and III
collagens7.
We will focus on type III collagen because only mutations in COL3A1 gene are widely studied as a
potential factor to cause vEDS. The type III procollagen molecule is assembled from three identical pro
α1 (III) chains. The N-pro-peptide domain contains specific structure which is part of the cleavage site.
The enzymes function at the site to remove propeptide. The C-propeptides of the procollagen are entirely
globular. After forming the triple helix structure, they are secreted to the extracellular area where they
undergo post translational modification and assembly to form mature collagen fibrils (Figure 1.4)
(Heritable diseases of collagen).

1.6

Mutation of COL3A1 gene leading to deficiency of type III collagen
Causative mutations are mainly identified in vEDS patients in the COL3A1 gene which locates at

position 31 of chromosome 2 (2q31)4 and encodes pro-type III collagen. Its transcription produces the proαI chain of type III collagen. Three αI chains are strictly assembled into a triple helix. To successfully
assemble a triple helix, a glycine residue is required the formation of a structure of (Gly-X-Y) n repeats.
The glycine residue locates at every third amino-acid of the polypeptide chain. This motif ensures the three
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αI chains forming a triple-helical structure (Figure 1.4). while residues X and Y adjacent the glycine
residue locating outside on the surface, all the other residues are buried within the protein9. Also, this motif
provides the stability of the collagen fibrils by increasing hydrogen bonding. The C-propeptide domain of
the procollagen is critical in initiating the process of trimerization. There are two major events involved in
trimerization: specific chain recognition and formation of a stable nucleus10. After folding into homotrimers, the collagen will be transported outside of the cells and into the extracellular matrix (ECM), where
it is processed enzymatically with different enzymes mainly metalloproteinases which belong to the
ADAMTS2 (a dis-integrin and a metalloproteinase with thrombospondin repeats)11. After the formation of
procollagen, the final step for the biosynthesis and assembling of collagens is the stabilization of the
supramolecular which is initiated by lysyl oxidases12. These super cross-links produce long, thin fibrils
that comprise the intercellular space. Individuals with COL3A1 gene mutations have severe defects in the

Figure 1.3 Fibroblast assembly of collagen fibrils
Panel A shows intracellular post-translational modifications of pro-α-chains, association of Cpropeptide domains, and folding into triple-helical conformation. Gal denotes galactose, Glc glucose,
GlcNac N-acetylglucosamine, and (Man)n mannose residues. Panel B shows enzymatic cleavage of
procollagen to collagen, self-assembly of collagen monomers into fibrils, and cross-linking of fibrils.
Reproduced with permission from [Heritable diseases of collagen. Prockop DJ, Kivirikko K. New
England Journal of Medicine. 1984], Copyright Massachusetts Medical Society.
overall structure of the type III pro-αI chain. Single nucleotide substitutions for the glycine residues are
the most common mutations which have been found within the COL3A1 gene. Gly substitution destabilizes

8

the structure of the triple helix. This results in decreased functional type III collagen. As of now, over 700
COL3A1 gene mutations have been identified, another mutation is the splicing skipping mutation. Both
types of mutations lead to equal production of abnormal and normal procollagen peptides, but because
collagen III is a homsotrimer formed by three identical procollagen peptides, such mutations lead to
production of a seven-to-one ratio of abnormal to normal collagen molecules, thus a minimal (MIN)
amount (10%-15%) of normal collagen is produced.
Some other mutations such as splicing at the level of transcription, deletion of the gene, and null
mutation have also been observed. Exon skip mutations result in an exon splicing error, which leads to a
frame shift mutation during the translation process. This results in premature degradation of the mutant
messenger RNA. This causes expression of a single gene thus termed haploinsufficiency (HI) which result
in only 50% of the normal amount of type III procollagen13. Clinically, people with haploinsufficient
COL3A1 mutations have a milder phenotype and an extended life expectancy as well as a later age at the
time of their first complication.

9

Figure 1.4 Fibrillar procollagens and fibril assembly
A. N- and C-terminal processing leads to spontaneous assemble of collagen fibrils, which are
subsequently stabilized by the formation of covalent-cross-links. B Domain structures of fibrillar
procollagen chains. Reproduced with permission from [Heritable diseases of collagen. Prockop DJ,
Kivirikko K. New England Journal of Medicine. 1984], Copyright Massachusetts Medical Society.

1.7

Increased Carotid wall stress in vEDS
Studies from Boutouyrie et al14, used a biomechanical method to detect if there are changes in arterial

wall mechanics that might predispose to dissection and rupture. In vEDS patients, there were 43% and 39%
higher in intimal medial ratio (IMT) and either internal diameter or midwall diameter compared to that in
control subjects. The feature seen in the arterial wall of vEDS patients may result from the reduction of
collagen I fibers.

10

1.8

vEDS and Col3a1 mice
The haploinsufficient Col3a1 mouse was generated by Liu et al. for study of the function of collagen

III in fibrillogenesis of collagen I and in development of cardiovascular system. The first exon as well as
the promoter of the Col3a1 gene was replaced with a PGK-neo cassette (a eukaryotic promoter (PGK)
with the expression of neomycin resistant gene in mammalian cells)15. The Col3a1-/- mouse was generated
from intercrosses of heterozygous mice15. About only 10% of the Col3a1-/- animals survive to adulthood,
while the rest of Col3a1-/-animals die with 3 days after birth. The most common reasons leading to the
death of Col3a1-/- mice is the rupture of vasculatures and colons, which are very similar to complications
in vEDS patients. Liu et al also performed ultrastructural analysis on tissues harvested from Col3a1-/- mice
which revealed that type III collagen plays a critical role in normal type I collagen fibrillogenesis, in the
development of cardiovascular as well as the function and development of other organs16.
To find out other structural defects in Col3a1+/- mice, they also carried out a detailed analysis with
electron microscopy for aorta and heart, (Figure 1.4) showing that the collagen fibrils were absent or
significantly decreased in the media of the Col3a1+/- aorta. At the same time, they also found that the fibril
number in Col3a+/- aorta decreased to even less than one third of that in Col3a1+/+ aorta while mean
diameter was significantly increased in Col3a+/- mice (Figure 1.5). In addition to the vascular system,
other tissues, such as the skin and lung of Col3a1+/- mice were also microscopically analyzed. It was found
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that the collagen I fibrils in the Col3a1+/- skin were both highly variable in diameter and disorganized in

Figure 1.5 Comparison of the diameters of collagen fibrils in the adventitia of
aorta of wild-type and mutant mice
A 2 mm 32 mm area in the adventitia of either wild-type or mutant aorta was randomly chosen, and all
the fibrils in this area were measured for their diameters and counted. Reproduced with permission
from [Heritable diseases of collagen. Prockop DJ, Kivirikko K. New England Journal of Medicine.
1984], Copyright Massachusetts Medical Society.
structure. Their results suggested that type III collagen was important in regulating the formation and
assembly of type I collagen fibrils, specifically the diameter. They concluded that the phenotypes shown
by the Col3a1-/- resembled to the clinical complications of vEDS patients.
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Cooper et al expanded Liu’s study and demonstrated that the Col3a1+/- could be used as a model for
vEDS17. They found that the collagen content the heterozygotes was reduced in the abdominal aorta, and
functional studies revealed diminished aortic wall strength in Col3a1+/- mice. There were also reduced
strength and increased wall compliance in the heterozygotes via pressure test. However, the mice did not
show life-threatening clinical signs nor did they develop gross vascular lesions which were similar to those
happen to vEDS patients. Overall, they suggested to generate a new mouse model with a single glycine
substitution which represent the severity of mutation for vEDS patients. However, few studies focus on
the mechanisms by which deficiency of type III collagen can cause vascular disease. Reid et al
(unpublished data) induced artificial injury of the left carotid artery by permanent ligation in both Col3a1+/heterozygous and Col3a1+/+ mice. By comparing the histological changes in the ligated Col3a1+/- and
Col3a1+/+ arteries, they found delayed thrombus resolution and increased formation of neo-vessels in the
medial layer of the artery in the Col3a1+/- mice after both 14 and 21 days of carotid artery ligation.

1.9

Myofibroblasts and wound healing
Numerous reports have investigated that cells derived from bone marrow (BMDs) or mesenchymal

originated cells such as fibroblasts, are important for remodeling after arterial injury18,19. During tissue
repair, fibrin clot formed at the injury site to further recruit inflammatory cells. The fibrin is soon followed
by various migrating cells that modulate the fibrin matrix, resulting in a collagenous scar20. These activated
fibroblasts produce critical components of ECM for the wound area. Then, the fibroblasts become
myofibroblasts and gain the ability to contract and generate contractile forces during repair. After all the
initial steps of wound repair, myofibroblasts disappear with the process of cell apoptosis. When
myofibroblasts persistent into differentiated myofibroblasts instead of dying, there will be extra ECM
components deposited, which are usually found in hypertrophic scar, as well as fibrotic processes in the
kidneys, heart, and lungs21.
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1.10 TGF-β signaling pathway and differentiation of fibroblasts
TGF-β1 is a cytokine secreted by platelets and fibroblasts and macrophages. In the classical TGF-β
signaling, three isoforms in TGF-β family of ligands are bound to receptor TβRI and TβRII. TβRII is
constitutively phosphorylated and further phosphorylates TβRI upon binding of the ligand. After that, the
intracellular SMAD signaling pathway will be activated by the receptor-ligand-complex through Smad-2,
Smad-3 and co-Smad4. SMAD proteins will then be translocated to the nucleus where they regulate
expression of a number of genes22. However, the differentiation of myofibroblasts from fibroblasts,
characterized by increased expression of SMA is first activated by TGF-β signaling and followed by FAK
signaling pathway as results shown by Thannickal et al23. In this study, they demonstrated that both TGFβ1 and FAK signals were required for a stable status of the myofibroblas. TGF-β1-induced myofibroblast
differentiation would be inhibited in non-adherent cells even if TGF β -Smad2 phosphorylation signaling
was active. Tyrosine phosphorylation of FAK induced by TGF-β1 which including Tyr-397 was also
delayed in relative to early TGF-β1-Smad signaling. Blockage of FAK or induction of FAK mutation could
inhibit expression of α-SMA, formation of stress fibers and cell proliferation induced by TGF-β1.

1.11

Neovascularization in arterial diseases
Rapid revascularization is essential in restoring organ function after injury, ischemia, or in

regenerating organs. An angiogenic switch often initiates the revascularization process, and this starts the
process of recruiting endothelial cells that assemble into neovessels24,25. However, because tissue injury
often prevents pre-existing endothelial cells (ECs) from performing their original function, exogenous
vascular progenitors might facilitate the restoration of re-vascularization. Adult bone marrow (BM)
provides different tissue specialized stem cells and other progenitor cells. There is a small cell population
known as epithelial progenitor cells (EPCs). These EPCs can circulate and contribute to the
neovascularization processes that promote rapid organ revascularization.
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The concept of fibrocyte was first described by Richard et al. in 1994 as circulating monocytederived cells, capable of expressing fibrotic phenotypes26. Monocytes derived fibrocytes show both
macrophages features and the tissue remodeling properties27. They uniquely co-express the haematopoietic
stem cell markers, CD45 and CD34. Fibrocytes also produce extracellular matrix (ECM) proteins. They
adopt a spindle shape and are present in wound exudates. Fibroblasts have remarkable plasticity in in vitro
studies, demonstrating their ability to be reprogrammed into haematopoietic appearance-wise, fibrocytes
also appear to be an intermediate between fibroblasts and macrophages. This phenotypical overlap could
be because fibrocytes are an intermediate population in the conversion of fibroblasts into macrophages,
and vice versa27. In injured tissues or inflammatory locations, fibrocytes can be induced into fibroblasts by
inflammatory factors to execute the function of ECM producing cells and function in injury repair or
wound healing27. In fact, it may be more appropriate to call them “fibrophages” or “macroblasts.”
Additionally, in injured tissues or locations of inflammation, fibrocytes can be induced to transform into
fibroblasts when in the presence of inflammatory factors. These new fibroblasts can then execute the same
functions of ECM-producing cells in injury repairing or wound healing. Studies from Desmoulière et al
proposed that fibrocytes derived from circulating precursor cells in the blood could be induced to
differentiate into fully functioning myofibroblasts; they express collagen and α-SMA, induce contractile
proteins, and contribute to thrombus resolution. More and more studies discover that the BM not only
originates hematopoietic cells for skin function, but dermal fibroblasts and myofibroblasts. Study from
Carrie Fathke et al. shows that bone marrow is significant more important to normal skin function and
healing cutaneous wounds than that had previously been recognized. In fact, of all dermal fibroblasts, 1520% were derived from the BM. This population of BM-derived dermal cells was more versatile than its
normal counterpart.

1.12

Previous studies in our lab on the Col3a1 mice
Prior in vivo studies by Dr. Amy Reid on the Col3a1 mice using an artificial arterial injury model at

the left carotid artery found that: 1) There is increased inflammatory response in the Col3a1+/- artery
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compared with that in the Col3a1+/+ artery; 2) There are persistent proliferative myofibroblasts in the
Col3a1+/- artery compared with that in the Col3a1+/+ artery; 3) There is increased new vessel formed in
the medial layer in the Col3a1+/- artery compared with that in the Col3a1+/+ artery. In vitro cellular studies
using 3D fibrinogen gel experiments, by comparing the dermal fibroblasts from vEDS patients and normal
control, demonstrating a dysfunctional matrix remodeling by myofibroblasts in vEDS patients.

Based on the prior findings, we hypothesize that fibroblasts from the bone marrow of Col3a1+/+ mice
can rescue the post-injury phenotypes in the Col3a1+/- mice and administration of celiprolol will be
able to alleviate post-injury phenotypes in Col3a1+/- mice. My dissertation research focused on the
following: 1. Confirm that haploinsufficiency in Col3a1 leads to aberrant wound healing after
vascular injury of Col3a1+/- mice; 2. Determine if bone marrow transplant rescues the aberrant
arterial injury repair of Col3a1+/- mice; 3. Assess if celiprolol treatment on the Col3a1 mice improves
aberrant injury repair in this model; 4. Understand the role of myofibroblasts in injury repair by in
vitro cellular study using cells explanted from Col3a1 mice.
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2

Bone Marrow Transplantation Rescues the Phenotypes in Col3a1+/- Mice
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2.1

Introduction
Vascular Ehlers-Danlos Syndrome (vEDS) patients have aberrant healing of their skin, such as easy

bruising, abnormal cutaneous scar appearance, and hypertrophic and fibrotic keloids28,29. The cutaneous
wound healing process repopulates and remodels the structural matrix of the tissue following injuries20.
There are three overlapping phases of the wound healing procedure (Figure 2.1): the inflammatory phase
from 3 to 7 days after injury, the tissue formation/proliferative phase from day 7 to day 14 followed by the
phase of tissue remodeling/contraction20,30.
The inflammatory phase includes the circulating inflammatory cells’ recruitment, infiltration and
activation at the injury site, resulting in formation of fibrin clot via chemo-attractants such as platelets as
well as activated macrophages produced transforming growth factor-β1 (TGF-β1)20. Monocytes infiltrate
to the injury site in response to certain chemo-attractants, such as fragments of ECM protein, TGF-β1 and
monocyte chemoattractant protein 1 (MCP-1). After infiltration, monocytes are activated and become
macrophages. Macrophages function as the sources to produce and release PDGF and VEGF. Both PDGF
and VEGF participate in initiating the formation of granulation tissue20. Signaling transduction by
macrophages critically promotes downstream injury repair activity by local cells20,30,31. The tissue
formation, also referred to as the proliferative phase, begins with the recruitment of macrophages followed
by activation of fibroblasts into the wound area where fibroblasts proliferate. TGF-β1 can both promote
the proliferation and differentiation of fibroblasts31. Myofibroblasts entails a great potency and striking
capacity for synthesizing ECM proteins and cellular contractility32. It was demonstrated that formation of
granulation tissues is a critical event in wound healing for vEDS patients and Col3a1+/- mice, because
conversion of fibrin clot after injury into collagenous matrix relies heavily on newly produced type I and
type III collagen32,33. As shown by a study in rats, along with neointimal formation after intraluminal injury,
there was a similar production of type I and type III collagens which were examined by qPCR to measure
the transcription of Col1a2 and Col3a1 genes34.
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We have demonstrated aberrant thrombus resolution in the Col3a1+/- mice (Amy Reid, unpublished
data). However, thrombus resolution progresses are similarly to wound healing, with evidence that the
fibroblast-type cells, termed fibrocytes, come from the bone marrow35. It has been shown that bone
marrow-derived (BMD) fibrocytes are important in wound healing35,36. Abe et al. also identified a potential
pathway through which blood-borne fibrocytes differentiate into myofibroblasts. It was postulated that
activated T cells could interact with circulating precursor cells of fibrocytes, triggering the early
differentiation of fibrocytes (toward the fibrocyte phenotype). Fibrocytes then migrate to the wound site,
where these early differentiated fibrocytes could further interact with T cells, which promote fully
differentiation and maturation of fibrocytes, termed as myofibroblasts with stimulation of TGF-β1. These
myofibroblasts then express α-Smooth muscle actin (α-SMA), produce collagen as well as other ECM
proteins that promote contracture and wound healing37. Finally, studies by Han et al. also showed a distinct
neointimal lineage cells that were originated from circulating BMD cells and participated in vascular injury
repair. These BMD neointimal cells also resemble stem cell-like fetal/immature vascular smooth muscle
cells (SMCs) or myofibroblasts38.
Neointimal SMCs proliferation occurs in vascular injuries, and most proliferative cells may come
from the arterial wall30. Many studies using the carotid injury model focus on resident SMCs proliferation
from the arterial wall. As reviewed by Daniel et al. SMCs contributing to the neointima formation after
arterial injury are primarily from the wall, and BMD progenitors rarely contribute to SMCs in neointima
formation39.
Fadini also reviewed that SMCs contributing to the formation of atherosclerosis are mostly from the
local arterial wall40. A study by Kawasaki using a mouse carotid artery ligation model shows that thrombus
formation and resolution is a prerequisite for neointimal formation41, and thrombus resolution also ensures
successful arterial injury repair42. Based on the current information, we speculate that immediately after
arterial injury, BMD fibrocytes circulate to the injury site to resolve the thrombi, followed by cells
migrating from the arterial wall for neointima formation to secure successful injury repair.
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Figure 2.1 Three over-lapping phases for wound healing

Myofibroblasts are in the three over-lapping wound healing process.
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2.2

Hypothesis
We hypothesize that deficiency of type III collagen results in aberrant vascular injury repair in vEDS

patients since their myofibroblasts are not producing sufficient type III collagen to effectively and
efficiently resolve thrombi after vascular injury. In the Col3a1+/- carotid ligation mouse model, after
induced ligation injury, arteries from Col3a1+/- mice show a persistent inflammation and proliferative cells,
presumably myofibroblasts, and increased medial neovessel formation. We hypothesize that the extended
thrombus resolution seen in Col3a1+/- arteries and the formation of neovessels in the wall, weaken that
wall and predispose to arterial events like dissection. We further hypothesize that by introducing BMD
fibrocytes with Col3a1+/+ genotype to Col3a1+/- mouse, these fibrocytes could then differentiate into
myofibroblasts with full expression of procollagen type III and correct the aberrant wound healing in
Col3a1+/- mice after carotid ligation. Therefore, we performed bone marrow transplant (BMT) of wildtype
bone marrow into the Col3a1+/- mice to test this hypothesis.

Specific aims：

(1) To replicate Dr. Amy Reid’s study results in 12 to14-week-old mice instead of 22 to 24week-old mice. This will confirm that the younger mice can be used for these studies.
(2) To perform a forward and reverse bone marrow transplant to rigorously address the stated
hypothesis.
a)

Assess the response and pathological changes to vascular injury in Col3a1+/- mice after
they receive bone marrow transplants (BMT) from Col3a1+/+ mice.

b)

Assess the response and pathological changes to vascular injury in reverse BMT, i.e.,
Col3a1+/+ mice after they receive a bone marrow transplant from Col3a1+/- mice.
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2.3

Methods

2.3.1

Carotid Ligation Injury

Mice used in the experiment (purchased from Jackson Laboratories, and bred in the animal facility of
UT McGovern Medical School at Houston) weighed between 25-30g. The animal study protocol was
approved by Animal Welfare Committee at UThealth at Houston. Mice were surgically ligated at the left
common carotid artery at the age of 12-14 weeks (unless otherwise stated). This age corresponds to the
mature adulthood phase in mice. The risk of fatal complications in vEDS patients increases within the age
range. However, there is no significance difference in risks for either complication or survival between
Col3a1+/+and Col3a1+/- mice.
The surgery procedure was modified from that described in Dr. Reid’s study (Amy Reid unpublished
data). Briefly, surgical mice were induced to anesthesia with 4% isoflurane which was maintained at 22.5% by a nose cone connected to the mouse. Aseptic techniques were used during the procedure and the
fur at the neck area was shaved off with Nair gel and sanitized with alcohol swabsticks. Afterwards,
analgesia with subcutaneous bupivacane (2.5 mg/kg) was applied immediately before making a midline
incision of 3mm in length in the neck with sterilized scissors. Followed by dissecting away the left common
carotid artery from the carotid sheath and vagus nerve. A ligature was made on the artery with 6-0 silk
suture immediately at the bifurcation site where the internal carotid arteries separate from external carotid
arteries. It was important to be gentle to avoid bleeding. The open skin area was irrigated with iodine
alcohol and closed by 2 interrupted stitches with 5-0 suture which would be absorbed after about one week.
About 10% of animals experienced stroke symptoms of during the first 7 post-operative days (POD7).
Mice which failed to maintain 80% of their body weight were sacrificed. About 5% of the mice died before
ligation due to massive bleeding caused by the procedure of carotid artery dissection. Mice that did not
show neurological phenotypes such as stroke were monitored and treated subcutaneous with ketoprofen
(2-5mg/kg) twice a day for 2 days after surgery. They were weighed daily and injected mice as needed
with 0.5-1ml lactated Ringer's solution based on their weight for over 10% drops. Normally mice would
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survive 95% after POD7. Mice were sacrificed on 7, 14 and 21 days after surgery for the different following
up experiments.

2.3.2

Histology studies
For studies and analysis of POD7 arteries (N = 6 Col3a1+/+, 6 Col3a1+/-), POD14 (N = 6 Col3a1+/+,

6Col3a1+/-), and POD21 (N = 5 Col3a1+/+, 5 Col3a1+/-), mice were first sacrificed, followed by puncturing
of the left ventricles with a 27-gauge needle. An incision was made on the right atria to allow the outflow
of perfusate. Mice were then perfused with phosphate-buffered saline (PBS) at <20 ml/min until blanching
of the liver completely. Mice were then perfused with 10ml of 10% formalin at the similar rate to fix
arteries in the native geometry. Both the entire lengths of carotid arteries were harvested for multiple
experiments.
Arteries were followed by fixing in 10% buffered formalin for about 24 hours. After fixation, arteries
were cleaned up and the connective tissues were removed followed by processing. After processing, the
arteries were left in fridge to chill up. Then the arteries were cut three times with a scalpel: one cut was
immediate to the ligature to remove the suture; a second cut was at the location of the descending aorta to
remove extra descending aorta; the third cut was in the mid-carotid artery. The remaining two pieces of
the artery were embedded with careful attention to maintain correct orientation. The entire block with
embedded artery was serial sectioned and three 5-µm-thick sections were collected per slide all through
the entire length of the arteries. Every tenth slide from the entire slides sequence was then performed with
hematoxylin and eosin (H&E) staining, followed by imaging a representative section on each slide. This
set of sequential images were enough for us to build up an entire arterial length along the axis of the arteries.
Each carotid artery could supply approximately 60 to 80 slides. All images in this dissertation were
presented at 20x, unless otherwise stated, and scale bars represent 100µm.
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2.3.3

Immunohistological (IHC) staining
The IHC staining method was modified from Dr. Reid’s study (unpublished data) and most of the

methods were similar with only minor corrections. Briefly, each arterial segments as obtained above from
H&E-staining provided a relative location of each segment with neointima formation. Those unstained
slide neighboring each neointima positive slide was subjected to IHC probes (Mac-2, pH3 and CD31) to
investigate the amount of macrophages, the number of actively proliferating cells locate within the
neointima and the neovascularization in the medial layer. The first slide was probed with Mac-2, which
showed the number of macrophages. The second local slide was used to measure the number of pH3positive nuclei. The third slide was subjected to CD31 which was used to detect endothelial cells that are
precursors for neovessels. Unstained sections were processed before heat-induced epitope retrieval (HIER
citrate pH 6.0) followed by blocking for 1 hour at room temperature.
For detecting the local macrophages, slides with arterial sections were probed with rat anti-mouse
Mac-2 primary antibodies (Cedarlane, Burlington, NC) and incubated for 1 hour at room temperature. For
detection of proliferative cells, slides with arterial sections were probed with with rabbit anti-mouse pH3
primary antibodies (Millipore, Billerica, MA) followed by incubation overnight at 4˚C. To examine
neovessel formation in formalin-fixed paraffin-embedded tissues, slides were left overnight at 4˚C with rat
anti-mouse CD31 antibodies (Dianova, Hamburg, Germany). Slides with arterial sections were then
washed with PBS, followed by incubation at room temperature for 1 hour with the appropriate biotinylated
secondary antibodies, and then tissues were probed with peroxidase-conjugated avidin/biotin complexes
(Vectastain ABC-AP Kit, Vector Laboratories, Burlingame, CA). Activity of peroxidase was detected
using a 3, 3’--diaminobenzidine (DAB) chromogen (Dako, Glostrup, Denmark). Slides were
counterstained with methyl green at the last step of staining.
For statistical analysis, slides were counted one by one to get the number of positive cells or vessels
independently. And then, for each genotype, a mean ±SD of positive cells was generated by averaging out
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all the number from each group from the pooled neointima-positive slides, representing Col3a1+/+or
Col3a1+/-. Significant differences were determined by the Student's t-test between the means (*p < .05).

2.3.4

Bone marrow transplant
Forward BMT by generating Col3a1/GFP chimeric mice
The green fluorescent protein transgenic (GFP+) marker was used to track cells from the donor mouse.

After BMT from Col3a1+/+ to Col3a1+/- mouse, the fibrocytes in the Col3a1+/- bone marrow would be
replaced by the GFP+ marked fibrocytes from the Col3a1+/+ genotype. Using this procedure, we generated
chimeric Col3a1+/+/GFP+ and Col3a1+/-/GFP+ mice. Engraftment of bone marrow was confirmed after 48 weeks by flow cytometry with the blood drawn from the tail vein of each animal upon sacrificing. Further
confirmation was done by immunofluorescent staining with GFP antibody to detect the expression of GFP
in the carotid artery section.

Forward BMT
BMT was performed in Col3a1 mice (6-8 weeks in age). Briefly, recipient mice were irradiated with
8Gy X-ray. The first 4Gy irradiation (usually 7pm) was given 12 hours before the second 4Gy irradiation
(usually 7am). Donor mice (CByJ.B6-Tg (CAG-EGFP) 1Osb/J) were sacrificed humanely, the skin of the
lower half was cut open, followed by spraying the animal down with 70% alcohol. The legs were removed
and the skin and muscles were removed by cutting skin off. Kim wipes were used to remove the muscles
by “rubbing”. Bones were transferred to a 100mm cell culture dish containing RPMI-1640 and the dish
was brought to tissue culture hood. Bones were rinsed with fresh RPMI-1640 and transferred to a new dish
with RPMI-1640. Femurs were separated from the tibia and fibula at the knee and the ends of the bones
were cut off followed by transferring the bones to a new dish containing RPMI-1640. All the bone marrow
cells were flushed out with a 27-gauge needle and syringe. This process was repeated with all bones until
all the bone marrow cells were collected. Bone marrow cells were passed through a 22-gauge needle for
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breaking up of all the clumps, then the large fragments in the cell suspension were removed by passing
through a cell strainer (40m) and bone marrow was then collected in a 50ml tube. 100-200L iced PBS
was added to the cells per mouse used, then the tubes were spun for 5 minutes at 500g or 1000rpm. Pellets
were re-suspended in iced PBS, and then the number of cells from bone marrow was counted with a
hemocytometer. Bone marrow was stored on ice until ready to inject. About 100-200l of bone marrow
(roughly 5-10 million cells) was injected retro-orbitally into the venous plexus of each lethally irradiated
and anesthetized recipient mouse 3-5 hours after second irradiation. Recipient mice were kept in irradiated
room and fed with irradiated chow as well as baytril water for 2 weeks. The 8Gy dosage control mice
would often die after 10-14 days, while the 4Gy dosage control mice could survive (100% survival). Bone
marrow cells repopulated in the lethally irradiated mice after a 4-8 weeks recovery.
Confirmation of chimera by flow cytometry
10l of blood from the tail vein was drawn from sacrificing mice. Blood was then lysed by cell lysis
buffer, (recipe: 0.155M NH4Cl, 0.01M KHCO3, 0.1mM Na2.EDTA.2H2O). Cells were then washed two
times with wash buffer (1% FBS in PBS) before conjugating with APC/Cy7 anti-mouse CD45 antibody
(Bio Legend Inc., CA) at 1:100 dilution, incubated at 4 degrees for 1 hour. After incubation, cells were
washed for two more times followed by loading onto Gallio’s Flow Cytometer (Beckman-Coulter Inc.,
CA) to detect the expression of GFP in the lymphocytes and analysis was achieved by using Kaluza
software.
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Reverse BMT
Similar to forward BMT, reverse BMT was performed in Col3a1 mice (aging 6-8 weeks). Briefly,
male recipient mice were irradiated with 8Gy X-ray. The first 4Gy irradiation (usually 7pm) was given 12
hours before the second 4Gy irradiation (usually 7am). The whole bone marrow cells were isolated from
humanely sacrificed female Col3a1+/- donor mice as described above. Bone marrow cells (5 million to
each recipient mouse) were re-suspended in sterile PBS and injected retro-orbitally into the recipient
Col3a1+/+ or Col3a1+/- mice. Chimeric male Col3a1+/+ mice with the expression of type III collagen from
circulating bone marrow cells of female Col3a1+/- donor mice were generated.

Confirmation of reverse BMT
Since all donor mice are female and all recipient mice are male, we designed a method to detect the
ratio of white blood cells from donor mice in recipient mice by measuring the ratio of mouse X and Y
chromosome content in blood from recipient mice. The idea of this method was based on a traditional
competitive RT-PCR for RNA quantification. By comparing homologous genes and sequences in mouse
X and Y chromosomes, we designed a set of primers in Zfx and Zfy genes. The primer sequences on these
genes were identical, forward primer: 5’- CATAGGCCTTCAGAACTCAAG and reverse primer: 5’CTTTCGTATGAATGGAGATAACG. To further validate this result, we designed a set of primers in
Usp9x and Usp9y genes and the primer sequences on these genes were identical, forward primer: 5’AACAGAATGAGCAGTCTGAAAG and reward primer: 5’- TCCACCATCTTTTCTGACGCC.
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2.4
2.4.1

Results
Increased neointimal formation after carotid arterial ligation in Col3a1+/- mice at POD21
To compare the injury response between Col3a1+/+ and Col3a1+/- mice, carotid ligation on the left

carotid arteries was performed in Col3a1+/+ and Col3a1+/- mice at around 12 weeks of age. Neointima
formation was examined over three weeks after surgery by H & E staining. On POD7 after ligation, the
Col3a1+/+ mice’s tissues exhibited a thicker neointimal layer compared to their Col3a1+/- counterparts. By
POD14 and POD21, the Col3a1+/+ mice had fully completed thrombus resolution, and the neointima of
their arteries had formed scars. At the same time, the Col3a1+/- arteries were still thickening its neointimal
layer. However, it has to be noted that the remodeling of neointima was slower in the arteries from
Col3a1+/- mice compared with that from Col3a1+/+ mice (Figure 2.2). To conclude, there was a slower
neointima remodeling in the Col3a1+/- arteries after carotid injury.

Figure 2.2 Slower neonitima remodeling in the Col3a1+/- mice
Representative cross sections of H&E-stained carotid arteries from both Col3a1+/+ and Col3a1+/- mice
after carotid ligation at POD7 (top panel), POD14 (middle panel) and POD21 (bottom panel), original
magnification, 100x
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2.4.2

Increased myofibroblast proliferation in the Col3a1+/- mice after carotid ligation
We next examined if there was difference in the accumulation of cells in the neointima using IHC

with an anti-pH3 antibody, to detect the cell mitosis marker pH3, which indicated the proliferative cells
within the arterial lumen. At POD7, there was no difference observed in cell proliferation comparing
Col3a1+/+ to Col3a1+/- tissues (Figure 2.3). However, at POD14 and POD21, cell proliferation in the
Col3a1+/- tissues was significantly higher. This indicated that Col3a1+/- mice have more neointimal
hyperplasia at later time points after arterial injury.
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Figure 2.3 Increased cell proliferation within the Col3a1+/- arteries
(a) Representative cross sections with anti-p-H3 staining (pH3, for proliferative cells) of carotid
arteries from both Col3a1+/+ and Col3a1+/- mice at 7, 14 and 21 days after carotid ligation. The
cellular proliferation marker showed no difference between Col3a1+/+ and Col3a1+/- arteries at 7
days after ligation but there was significant increased pH3 positive cells in the Col3a1+/- arteries
compared with that in the Col3a1+/+ arteries at both 14 and 21 days after ligation. Original
magnification 400x, and scale bars: 50μm, red arrow was showing the pH3 positive cell (b)
Quantitation: showed that there was increased cell proliferation in the arteries from Col3a1+/- mice
by POD14 and POD21 compared with that from the Col3a1+/+ mice. n = 6 per group. **p<0.01，
p***<0.001 by Student’s t-test, NS: no significance.
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2.4.3

Increased inflammation in Col3a1+/- mice after carotid ligation
In Dr. Amy Reid’s unpublished data, there was increased macrophage burden in the Col3a1+/- arteries

at later time points. To determine if consistent phenotype existed in younger mice, we examined
inflammation status with tissues from these mice. Arterial sections with tissues from POD7, POD14, and
POD21 arteries were probed with mouse macrophage marker, Mac-2. Mac-2 positive cells in the
neointima were counted in all sections. Result showed no significant difference in macrophage
accumulation at POD7 (Figure 2.4b). However, we found a significantly increased number of
macrophages in Col3a1+/- arteries per section at POD14 and POD21 arteries. There were very few
remaining inflammatory cells in the Col3a1+/+ sections by POD21. By contrast, Mac-2 positive cells are
still present at high numbers in the Col3a1+/- arteries through POD21 (Figure 2.4b). These results
indicated the increased inflammation in the Col3a1+/- mice after carotid injury.
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Figure 2.4 Increased inflammation within the Col3a1+/-arteries
(a) Representative cross sections with anti-Mac-2 staining (Mac-2, for inflammatory cells) of
carotid arteries from both Col3a1+/+ and Col3a1+/- mice at 21 days after carotid ligation. The
inflammatory marker showed no difference between Col3a1+/+ and Col3a1+/- arteries at 7 days after
ligation but showed an increase in Mac-2 positive cells in the Col3a1+/- arteries at both 14 and 21
days after ligation, and there was a trend in increased Mac-2 stained cells in the Col3a1+/- arteries
from 7 days after ligation and persistent up until 14 and 21 days while a significant decrease in
Mac-2 stained cells from 7 days to 21 days in the Col3a1+/+ arteries. Original magnification 400x,
scale bars: 50μm, red arrow was showing the Mac-2 positive cell (b) Quantitation: showed increased
inflammation in the arteries from Col3a1+/- mice by POD14 and POD21. n = 6 per group. *p<0.05，
p**<0.01 by Student’s t-test, NS: no significance.
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2.4.4

Persistent neovascularization in the media of injured Col3a1+/- arteries at POD21
Neovascularization was driven by VEGF and other cytokines secreted by platelets and macrophages.

It plays an important role in venous thrombus resolution 43,44. Dr. Reid observed some blood-filled
neovessels within the media of Col3a1+/- arteries, while fewer or no neovessels were found in the arteries
of the Col3a1+/+ mice. To determine if neovessel formation could also be observed in the younger mice,
immunostaining for immature endothelial cells lined within the arterial lumen using an antibody directed
against CD31 was conducted. Data showed consistently increased numbers of neovessels in the medial
layer at POD14 and POD21 in the Col3a1+/+ arteries (Figure 2.5). We speculate that persistent
inflammation in the Col3a1+/- arteries drive continuous secretion of VEGF and further drive the formation
of neovessels in the arterial wall which predispose the fragility of arterial wall in the Col3a1+/- mice.
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Figure 2.5 Increased medial neovessel formation in Col3a1+/- arteries
(a) Representative cross sections with anti-CD31 staining (CD31, for vascular endothelial cells) of
carotid arteries from both Col3a1+/+ and Col3a1+/- mice at 7, 14 and 21 days after carotid ligation. The
endothelial marker didn’t showed any differences between Col3a1+/+ and Col3a1+/- arteries at 7 days
after ligation but there was significant increased CD31 positive neovessels in the Col3a1+/- arteries
compared with that in the Col3a1+/+ arteries at both 14 and 21 days after ligation. Original magnification
400x, scale bar: 50μm, red arrow was showing the CD31 positive neovessel. (b) Quantitation: showed
increased neovessels in the medial layer of the arteries from Col3a1+/- mice by POD14 and POD21
compared with that from the Col3a1+/+ mice. n = 6 per group. *p < 0.05, by Student’s t test, NS: no
significance.
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2.4.5

Bone marrow from the Col3a1+/+ mice recuses the ability of injury repair in Col31+/- mice
Data from the first section of this chapter confirmed the aberrant injury repair in the Col3a1+/-mice.

Myofibroblasts which produce collagens to the extracellular matrix are widely accepted to be critical in
injury repair45. Fibrocytes, which can be differentiated into fibroblasts and further induced into
myofibroblasts are derived from fibrocytes in the bone marrow21. We hypothesize that deficiency of type
III collagen results in an aberrant vascular injury repair in vEDS patients since their myofibroblasts are
not producing sufficient type III collagen to effectively and efficiently resolve thrombi after vascular
injury. In Col3a1+/- carotid ligation mouse model, after induced ligation injury, arteries from Col3a1+/mice showed persistent inflammation and proliferative cells, presumably myofibroblasts, and increased
medial neovessel formation. We hypothesize that the extended thrombus resolution seen in Col3a1+/arteries and formation of neovessels in the wall weaken that wall and predispose to arterial events like
dissection. We further hypothesize that introducing BMD fibrocytes with Col3a1+/+ genotype to
Col3a1+/- mouse, these fibrocytes could then differentiate into myofibroblasts with full expression of
procollagen type III and correct the aberrant wound healing in Col3a1+/- mice after carotid ligation.
Therefore, we performed bone marrow transplant (BMT) of wildtype bone marrow into the Col3a1+/mice to test this hypothesis.
First, bone marrow from the Col3a1+/+ mice was collected and transplanted to both the Col3a1+/+ and
Col3a1+/- mice. Figure 2.6 shows the flow chart of the forward BMT experiment. After waiting for 4-8
weeks, irradiated mice were sacrificed and the efficiency of BMT was confirmed by flow cytometry to
detect the expression of GFP marker on lymphocytes. Figure 2.7a showed the expression of GFP on
more than 80% of the lymphocytes indicating successful BMT. IHC staining with an anti-GFP antibody
(Abcam，Cambridge, United Kingdom) was performed to detect GFP positive cells within the neointima
and the arterial lumen to confirm that a chimera was obtained (Figure 2.7b). GFP positive cells were
detected within the lumen as well as the neointimal layer indicating a contribution of BMDCs to the
formation of the neointimal layer. Following the confirmation of successful BMT, IHC staining as stated
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in 2.2.1 was performed to examine the proliferation of myofibroblasts in the neointima, inflammation in
the neointima and neo-vessel formation in the medial layer. But for this study we only looked at the
POD14 and POD21 since the difference between Col3a1+/+ and Col3a1+/- at POD7 is not as dramatic as
the difference seen at POD14 and POD21.

Figure 2.6 Flow chart for Forward BMT
Forward Bone Marrow Transplant (BMT) – F-BMT. Bone marrow was isolated from the
Col3a1+/+mice and transplant to both X-ray lethally irradiated Col3a1+/+ and Col3a1+/- recipient
mice. Bone marrow repopulated in the recipient mice for 4-8 weeks before performing carotid
ligation, mice were sacrificed and carotid arteries harvested for following up histology studies.
About 20μl mice peripheral blood from tail vein was saved for flow cytometry to detect the
expression of GFP confirm the efficiency of BMT. F-BMT: Forward bone marrow
transplantation, bone marrow from Col3a1+/+ mice was transplanted into both Col3a1+/+ and
Col3a1+/- mice.
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Figure 2.7 Confirmation of F-BMTF-BMT
(a) Expression of GFP in the lymphocytes detected by flow cytometry, positive GFP signal
indicated successful BMT. (b) IHC staining to confirm the efficiency of BMT with the detection
of GFP in the neointima in ligated arteries. NC: negative control of GFP, PC: positive control
of GFP staining. (c): red arrow was showing positive GFP cell. GFP positive cells showed in
the neointima indicating that BMD cells circulated to the injury site. F-BMT: forward bone
marrow transplantation, bone marrow from Col3a1+/+ mice was transplanted into both
Col3a1+/+ and Col3a1+/- mice.

37

To examine the difference in neointima remodeling between two groups of mice after forward BMT,
H & E staining was also performed. Result showed no significant difference after forward BMT at POD14
and POD21 in both Col3a1+/+ and Col3a1+/+mice, indicating the ability of neointimal remodeling was
similar in both groups of arteries (Figure 2.8). Additionally, cell proliferation ability was again determined
by pH3 staining. Again, the number of pH3 positive cells didn’t show significant difference within the
neointima by POD21, indicating no dramatic difference in the proliferation of cells in the neointima
(Figure 2.9) after 21 days of injury with forward BMT. Inflammation was also determined by Mac-2
staining. Significant difference was still observed in the inflammation level in the neointima between
Col3a1+/+ and Col3a1+/+mice at POD14 and POD21 (Figure 2.9 and 2.10). CD31 stained neovessels were
also counted and results showed no significant difference in the capability of neovessel formation in the
medial layer, indicating that the neovessel formation ability was also reduced back to Col3a1+/+ levels in
Col3a1+/- BMT mice at POD14 and POD21 (Figure 2.11). These data indicate that transplantation of bone
marrow from the Col3a1+/+ mice could normalize the injury repair in the Col3a1+/- mice especially by
POD21.

Figure 2.8 Similar ability in neointimal remodeling after F-BMT

Representative H&E-stained cross sections of carotid arteries from both Col3a1+/+ and
Col3a1+/- mice after carotid ligation at POD14 (top panel) and POD21 (lower panel), original
magnification, 100x. F-BMT: Forward bone marrow transplantation, bone marrow from
Col3a1+/+ mice was transplanted into both Col3a1+/+ and Col3a1+/- mice.
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Figure 2.9 Decreased cell proliferation in Col3a1+/- arteries after F-BMT
(a) Representative cross sections with anti-p-H3 staining (pH3, for proliferative cells) of
carotid arteries from both Col3a+/+ and Col3a1+/- mice at 14 and 21 days after carotid ligation.
There was still significant more pH3 positive cells in the neointima of Col3a1+/- arteries
compared with that in the neointima of Col3a1+/+ arteries at 14 days after ligation. While there
was no differences between Col3a1+/+ and Col3a1+/- arteries at 21 days after ligation from
mice with F-BMT. And a significant decrease in pH3 positive cells in the neointima of
Col3a1+/- arteries at POD21 arteries compared that from the POD14 arteries in Col3a1+/- mice.
Original magnification 400x, red arrow was showing the pH3 positive cell (b) Quantitation:
showed decreased cell proliferation in the Col3a1+/- arteries to the level of that in arteries from
Col3a1+/+ mice from POD14 to POD21 indicating decreased neointimal formation after FBMT in Col3a1+/- arteries. n = 6 per group. *p < 0.05, p**< 0.01 by Student’s t test, NS: no
significance. F-BMT: Forward bone marrow transplantation, bone marrow from
Col3a1+/+ mice was transplanted into both Col3a1+/+ and Col3a1+/- mice.
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Figure 2.10 Decreased neointimal inflammation in Col3a1+/- arteries after F-BMT
(a) Anti-Mac-2 staining (Mac-2, for inflammatory cells) of representative cross sections of carotid
arteries from both Col3a1+/+ and Col3a1+/- mice at 14 and 21 days after carotid ligation with F-BMT.
The Mac-2 staining showed significant difference in the number of Mac-2 stained cells in the Col3a1+/arteries compared with that in the Col3a1+/+ arteries at both 14 and 21 days after ligation with FBMT. Original magnification 400x, scale bars: 50μm. Red arrow was showing the inflammatory Mac2 positive cell (b) Quantitation: shows decreased inflammation in the Col3a1+/- arteries to the level of
that in arteries from Col3a1+/+ mice POD21 indicating similar ability in neointimal inflammation after
F-BMT in both Col3a1+/+ and Col3a1+/- arteries at both POD14 and POD21. n = 6 per group. NS: no
significance by Student’s t-test, F-BMT: Forward bone marrow transplantation, bone marrow from
Col3a1+/+ mice was transplanted into both Col3a1+/+ and Col3a1+/- mice.
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2.4.6

Reverse Bone Marrow Transplantation worsens the phenotypes shown in the Col3a1+/+
mice
Results from the forward BMT showed the potential for Col3a1+/+ bone marrow to correct the injury

repair ability of Col3a1+/- mice. This indicated that bone marrow-derived cells from the Col3a1+/+ mice
became myofibroblasts that secrete and lay down collagen fibrils to accelerate the arterial injury repair
process which was delayed in the Col3a1+/- mice before transplant. Based on these results, we then asked
whether bone marrow from Col3a1+/- mice would worsen post-injury phenotypes in the Col3a1+/+ arteries.
Reverse BMT was performed on both Col3a1+/+ and Col3a1+/- mice. Shown in Figure 2.12 was the
flow chart for the reverse BMT. As before, the recipient mice were lethally irradiated with 8Gy X-ray and
bone marrow from female Col3a1+/- donor mice was collected and injected retro-orbitally into the recipient
male mice. After recovery for 4-8 weeks, carotid artery ligation was also made with the recipient mice.
Carotid arteries from the ligated recipient mice were collected as described before at both POD14 and
POD21. Upon harvesting samples, blood was collected from the heart in order to isolate DNA to be used
for confirmation of a successful reverse BMT. Liver tissues were collected for isolating DNA to confirm
the success of the reverse BMT. Confirmation of reverse BMT was shown in Figure 2.13. Sanger
sequencing assay on the PCR fragments showed that DNA from a female mouse is homozygous Zfx while
DNA from a male mouse was heterozygous on some nucleotides that were from the sequence diversity
between Zfx and Zfy (Figure 2.13, the first row). The different alleles of each heterozygous nucleotide
have similar peak height based on Sanger sequencing, which indicated that the primers had similar
efficiency to amplify fragments in Zfx and Zfy (Figure 2.13, the first row).
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PCR and sequencing assay were performed with DNA extracted from the blood samples of recipient
mice. The results showed that Y chromosome Zfy was undetectable in recipients’ blood samples (Figure
2.13, left column, row 2-4). To validate this finding, we performed PCR and sequencing assay with DNA
extracted from livers of recipient mice. The result showed that the amount of Y chromosomes in livers of

Figure 2.11 Decreased neovessel formation in the Col3a1+/- arteries after F-BMT
(a) Representative cross sections with anti-CD31 staining (CD31, marker of endothelial cells) of
carotid arteries from both Col3a1+/+ and Col3a1+/- mice at 14 days after carotid ligation with FBMT. The CD31 staining showed that there was no significant difference in the number of CD31
positive neovessels in the Col3a1+/-arteries compared with that in the Col3a1+/+ arteries at both 14
and 21 days after ligation from mice with F-BMT. Original magnification 400x, and scale bars:
50μm. Red arrow was showing the CD31 positive neovessels in the medial layer (b) Quantitation:
showed similar number of neovessels in the Col3a1+/- arteries compared to Col3a1+/+ mice after FBMT. n = 6 per group. NS: no significance, by Student’s t-test. F-BMT: Forward bone marrow
transplantation, bone marrow from Col3a1+/+ mice was transplanted into both Col3a1+/+ and
Col3a1+/- mice.
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the recipient mice were similar to that of X chromosomes (Figure 2.13, right column, row 2-4). To further
validate this result, we designed a set of primers in Usp9x and Usp9y genes and the primer sequences on
these genes were identical, forward primer: 5’-AACAGAATGAGCAGTCTGAAAG and reward primer:
5’- TCCACCATCTTTTCTGACGCC. The sequencing results confirmed our previous finding that the
majority of white blood cells in recipient mice were from donor animals 4-8 weeks after transfusion.
(Figure 2.13, row 5). Overall, this result suggested that the majority of white blood cells in the recipient
mice were from donors 4-8 weeks after the bone marrow transfusion, indicating a successful reverse BMT.
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Figure 2.12 Flow chart for Reverse Bone Marrow Transplant (BMT)
– R-BMT
Bone marrow was isolated from the Col3a1+/- female mice and transplanted to both X-ray lethally
irradiated Col3a1+/+ and Col3a1+/- male recipient mice, the bone marrow repopulated in the
recipient mice for 4-8 weeks before performing carotid ligation, mice were sacrificed and carotid
arteries harvested for following up histology studies. 500ul mice peripheral blood and liver tissue
from both donor and recipient mice was saved for the confirmation of R-BMT. R-BMT: reverse
Bone Marrow Transplant, bone marrow from Col3a1+/- female mice was transplanted to both
Col3a1+/+ and Col3a1+/- male mice.
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Figure 2.13 Confirmation of R-BMT
PCR and sequencing assay were performed with DNA extracted from both blood and livers of recipient
mice. M: male; F: female; b: blood; l: liver, numbers are the mouse identification number. PCR and
sequencing results showed that there was donor originated Zfx and Zfy detected in the DNA extracted
from recipient blood samples, but not detected in the DNA extracted from recipient liver tissue
indicating the repopulation of donor bone marrow in the recipient mice. R-BMT: reverse Bone
Marrow Transplant, bone marrow from Col3a1+/- female mice was transplanted to both Col3a1+/+ and
Col3a1+/- male mice.
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Figure 2.14 Similar ability in neointimal remodeling after R-BMT
Representative H&E-stained cross sections of carotid arteries from both Col3a1+/+ and
Col3a1+/- mice after carotid ligation at POD14 (top panel) and POD21 (lower panel). Results
show similar ability in neointimal remodeling in the Col3a1+/+ and Col3a1+/- mice after carotid
ligation with R-BMT at both POD14 and POD21. Original magnification, 100x. R-BMT:
Reverse bone marrow transplantation, bone marrow from Col3a1+/- female mice was
transplanted to both Col3a1+/+ and Col3a1+/- male mice.
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Figure 2.15 No significant difference in cell proliferation after R-BMT

(a) Representative cross sections with anti-p-H3 staining (pH3, for proliferative cells) of
carotid arteries from both Col3a1+/+ and Col3a1+/- mice at 14 and 21 days after carotid ligation
with R-BMT. No difference between Col3a1+/+ and Col3a1+/- arteries at both 14 and 21 days
after ligation from mice with R-BMT was observed. Original magnification: 400x, scale bars:
50μm, red arrow was showing the pH3 positive cell (b) Quantitation: shows no difference in
the pH3 positive cell of arteries from both Col3a1+/+ and Col3a1+/- at POD14 and POD21
indicating similar ability in cell proliferation within the arterial lumen after R-BMT. n = 6 per
group. NS: no significance by Student’s t test. R-BMT: Reverse bone marrow
transplantation: bone marrow from Col3a1+/- female mice was transplanted to both Col3a1+/+
and Col3a1+/- male mice.
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Figure 2.16 No significant difference in neointimal inflammation after R-BMT
(a) Representative cross sections with anti-Mac-2 staining (Mac-2, for inflammatory cells) of carotid
arteries from both Col3a1+/+ and Col3a1+/- mice at 14 and 21 days after carotid ligation with R-BMT.
The inflammatory marker showed that there was not significant difference in Mac-2 stained cells in the
Col3a1+/- arteries comparing to that in the Col3a1+/+ arteries at both 14 and 21 days after ligation with
R-BMT, but there was significant increase in Mac-2 positive cells from POD14 to POD21 in the arteries
from Col3a1+/+ compared with that in the Col3a1+/- after R-BMT. Original magnification 400x, and
scale bars: 50μm, red arrow is showing the inflammatory Mac-2 positive cell (b) Quantitation: shows
no difference in the neointimal inflammation in arteries from both Col3a1+/+ and Col3a1+/- after RBMT. n = 6 per group. ***p < 0.001, by Student’s t-test, NS: no significance. R-BMT: Reverse bone
marrow transplantation, bone marrow from Col3a1+/- female mice was transplanted to both Col3a1+/+
and Col3a1+/- male mice.
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After reverse BMT, the formation of neointima, cell proliferation, inflammation in the neointima, and
neovessel formation in the medial layer were all investigated. First, H&E staining was still performed to
examine the neointima hyperplasia. Results from the H&E staining showed increased neointima in sections
from both groups of mice from POD14 to POD21 (Figure 2.14) and results from the pH3 staining showed
that there were significantly more pH3 stained cells in the neointima of arteries from Col3a1+/+ mice at
POD21 compared with that in the neointima of arteries from Col3a1+/+ arteries at POD14, indicating
increased cell proliferation in the Col3a1+/+ arteries after 21 days of injury (Figure 2.15). Interestingly,
there was increased quantity of Mac-2 positive cells detected in the neointima layer in Col3a1+/+ mice after
reverse BMT at POD21 compared with that in the Col3a1+/+ arteries at POD14 (Figure 2.16), suggesting
increased inflammation in Col3a1+/+ mice after reverse BMT. There was no difference in neovessel
formation after reverse BMT at both POD14 and POD21 in both groups of arteries (Figure 2.17). To
conclude, after reversal BMT, we found an increase in cell proliferation in the Col3a1+/+ mice at POD21
compared to POD14, an increase in inflammation in the neointima in the Col3a1+/+ mice at POD21
compared to POD14, but we were not able to see any difference in the neovessel formation in both groups
of mice at both time points.
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Figure 2.17 No significant in neovessel formation arteries after R-BMT
(a) Anti-CD31 staining (CD31, for endothelial cells) of representative cross sections of carotid
arteries from both Col3a1+/+ and Col3a1+/- mice at 14 and 21 days after carotid ligation with RBMT. The CD31 staining shows that there was no significant difference in the number of CD31
positive neovessel in the Col3a1+/- arteries compared with that in the Col3a1+/+ arteries at both
14 and 21 days after ligation with R-BMT. Original magnification 400x, scale bars: 50μm. Red
arrow was showing CD31 positive neovessel (b) Quantitation: showed the neovessel formation
in the medial layer in the Col3a1+/- arteries was similar to the level of that in arteries from
Col3a1+/+ mice both POD14 and POD21 after R-BMT. n = 6 per group, NS: no significance by
Student’s t-test. R-BMT: Reverse bone marrow transplantation, bone marrow from
Col3a1+/- female mice was transplanted to both Col3a1+/+ and Col3a1+/- male mice.
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Figure 2.18 H&E staining indicating changes in the neointima remodeling
Representative sections of the Col3a1+/+and Col3a1+/- mice after carotid ligation with No BMT (top
panel), F BMT (middle panel) and R BMT (bottom panel) at both POD14 (left panel) and POD21 (right
panel). Showing decreased neointima formation after F-BMT while increased neointima formation after
R-BMT compared with that in arteries from mice with no BMT at both POD14 and POD21, especially
in Col3a1+/- mice at POD21. Scale bar: 100μm. (BMT: bone marrow transplant, F-BMT: forward BMT,
R-BMT: reverse BMT).
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Figure 2.19 Comparison of cell proliferation in the neointima for all groups
(a) pH3 staining showed representative sections of arteries from both Col3a1+/+ and
Col3a1+/- mice, after carotid ligation with No-BMT (top panel), F-BMT (middle
panel) R-BMT (bottom panel) at both POD14 (left panel) and POD21 (right panel)
original magnification 200x. (b) Quantitation showed significantly higher number
of pH3 positive cells in arteries from Col3a1+/- mice compared with that in arteries
from Col3a1+/+ mice in No-BMT group at both POD14 and POD21. There was no
difference in the number of pH3 positive cells in arteries from both Col3a1+/+ and
Col3a1+/- mice at both POD14 and POD21 after F-BMT. There was significantly
decreased number of pH3 positive cells in arteries from Col3a1+/- mice after FBMT compared with that in No-BMT at POD 21. However, there was significant
increase in the number of pH3 cells in arteries from Col3a1+/+ mice after R-BMT
compared with that from No-BMT arteries at POD21. (BMT: bone marrow
transplant, F-BMT: forward BMT, R-BMT: reverse BMT), *p<0.05,
**p<0.01, ***p<0.001 by Student’s t-test, NS: no significance.
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Figure 2.20 Comparison of inflammation in the neointimal layer for all groups
(a) Mac-2 staining showed representative sections of arteries from both Col3a1+/+ and
Col3a1+/- mice, after carotid ligation with No-BMT (top panel), F-BMT (middle panel) and
R-BMT (bottom panel) at both POD14 (left panel) and POD21 (right panel). (b) Quantitation
showed that there was significantly higher number of Mac-2 positive cell in arteries from
Col3a1+/- mice compared with that in arteries from Col3a1+/+ mice at both 14 and 21 days
after ligation in No-BMT group, and there was no significant difference in the number of
Mac-2 positive cells in arteries from Col3a1+/+ mice compared with Col3a1+/- arteries at
POD21 after F-BMT. There were significantly more Mac-2 cells in arteries from Col3a1+/+
mice with R-BMT compared with those from Col3a1+/+ mice in No-BMT and F-BMT group
at POD21. (BMT: bone marrow transplant, F-BMT: forward BMT, R-BMT: reverse
BMT), *p<0.05, **p<0.01, ***p<0.001 by Student’s t test, NS: no significance.
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Figure 2.21 Comparison of medial neovessel formation
for all groups
(a) Representative sections of arteries from both Col3a1+/+ and Col3a1+/- mice after carotid
ligation with No-BMT (top panel), F-BMT (middle panel) and R- BMT (bottom panel) at both
POD14 (left panel) and POD21 (right panel) (b) Quantitation showed that there was
significantly higher number of new vessels in arteries from Col3a1+/- mice compared with that
from Col3a1+/+ mice in no BMT group at 14 and 21 days after ligation and there was no
significant difference in the number CD31 positive neovessel in arteries from Col3a1+/+ mice
compared with arteries from Col3a1+/- mice after F-BMT and R-BMT groups at both POD14
and POD21, indicating no difference in neovessel formation in the medial layer after F- and RBMT. *p<0.05 by the Student’s t test, NS: no significance.
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Discussion
Data generated from Col3a1+/- mice showed a decreased expression and production of mature type III
collagen by fibroblasts/myofibroblasts in injured carotid arteries, leading to delayed thrombus resolution
as described in Dr. Reid’s study (Unpublished data). The study described herein confirmed and expanded
the finding of delayed thrombus resolution in the Col3a1+/- mice. In Col3a1+/+ mice, there was an initial
response that lead to the appearance of thrombus at POD7. This was accompanied by the presence of
macrophages in the lumen space. However, by POD14, the size of the neointima was already decreasing,
and by POD21 the neointima has decreased to a relatively thin layer. By contrast, in the Col3a1+/- mice the
initial response was slower, such that at POD7 there was actually less neointima than in the Col3a1+/+.
However, the number of proliferating and infiltrating cells was higher in the Col3a1+/- mice. At POD14
and POD21 the size of the neointima continued to increase in the Col3a1+/- mice. The thickening of
neointimal layers in Col3a1+/- tissues at POD14 and POD21 was consistent with results from Dr. Reid’s
study (Unpublished data). This delayed wound healing in Col3a1+/- mice suggested that expression of
correct type III collagens was necessary for quick and complete thrombus resolution. Taken together, these
results showed that the Col3a1+/- mice have delayed thrombus resolution as a result of reduced type III
collagen production.
Macrophage participation in inflammation was critical in successful wound healing by secreting
inflammatory factors and pro-angiogenic factor-VEGF. Both secure a normal and successful wound
healing46. However, when there is not enough type III collagen laid down at the wound site, there is a
continuous need for myofibroblast proliferation, resulting in a persistent existence of macrophages and
inflammation. Extra TGF-β from macrophages are involved in the differentiation of myofibroblasts to
produce procollagen type III, while extra VEGF result in medial neovessel formation, which predisposes
the arterial dissection and rupture47. Macrophages have different functions in wound healing. Expression
of growth factors and/or angiogenic factors such as TGF-β and VEGF by macrophages are both critical in
persistent wounding and scarring46.
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We proposed that myofibroblasts functioning at the injury site originated from the circulating
fibrocytes in the bone marrow, and therefore hypothesized that BMT could be a potential strategy to correct
the defective injury repair in Col3a1+/- mice. In principal, transplanted BMD cells from Col3a1+/+ mice
could circulate to the injury site, expressed and lay down mature type III collagen48, thus accelerating the
process of thrombus resolution. Results from the forward BMT showed that at POD14 and POD21 the
neointimal thickening in Col3a1+/- arteries was reduced back to the level that was observed in the arteries
from Col3a1+/+mice (Figure 2.18). Additionally, the proliferation and inflammation in the Col3a1+/arteries was reduced to similar levels as Col3a1+/+ arteries (Figure 2.19 and 2.20). Less neovessel
formation in the medial layer was also observed, suggesting that preventing the exaggerated proliferative
and inflammatory response also reduced expression of angiogenic factors (Figure 2.21). These results
support our hypothesis that after receiving bone marrow from the Col3a1+/+mice, fibrocytes circulate to
the wound area and produce type III collagen to promote wound repair by decreasing aberrant cell
proliferation and inflammation as well as neovessel formation in the Col3a1+/- arteries.
Bone marrow-derived cells as well as resident fibroblasts contribute to the arterial injury process after
tissue injury38,49. However, it is still controversial whether the circulating cells or the resident cells
contribute to repairing at the injury site. From our forward BMT study, we demonstrated by GFP staining
that cells from circulation migrate to the injury site (Figure 2.7). To confirm the discoveries, we
hypothesized that transplanting bone marrow from the Col3a1+/- mice into the Col3a1+/+ mice would
exacerbate the phenotypes in the Col3a1+/+ arteries by contributing circulating Col3a1+/- fibrocytes which
will be induced and differentiated into myofibroblasts, this will lead to a delayed arterial injury in the
Col3a1+/+ arteries. To test our hypothesis, reverse BMT was performed.
Results from the reverse BMT validated our hypothesis. We observed increased cell proliferation
in the neointima layer in the Col3a1+/+ mice after reverse BMT at POD21 compared with arteries from
non-BMT Col3a1+/+ mice (Figure 2.18 and 2.19). Furthermore, we observed increased inflammation
levels in the neointima in the Col3a1+/+ mice after reverse BMT at POD21 (Figure 2.20).
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In conclusion, the current study confirmed a novel mechanism for the vascular phenotypes in
vEDS patients. More importantly, we have tested a novel therapeutic approach of BMT to treat the vascular
complications of vEDS by correcting injury repair ability of vEDS patients. This study provided a
possibility to dramatically improve the length and quality of life for vEDS patients and decrease the
incidence of sudden death caused by arterial events, including dissections and arterial rupture4.

57

3

Celiprolol Trial on Col3a1+/- Mice to Modulate the Thrombus Resolution
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3.1
3.1.1

Introduction
β-adrenergic receptors (β-ARs) and wound healing
Beta-adrenergic receptors (β-ARs) are playing a central role to the regulation in cardiac function50.

These receptors are located on the surface of many cell types and bound to endogenous hormones such as
catecholamine and norepinephrine51. The “β2-AR subtype” of β-ARs is distributed on the membrane of
fibroblasts, keratinocytes and melanocytes52. Although the expression of β2-AR subtype on skin tissues
has been identified for more than three decades, their functional significance was not recognized until
recently53.
The complicated skin wound healing process requires a series of coordinated procedures. Temporal
and orchestration of numerous cell types which parallel with thrombus resolution, as discussed in Chapter
2, all together, they provide a successful wound healing mice model. Although different studies have
provided evidences that a β2-AR autocrine/paracrine singling pathway exists, a clear understanding of the
specific role for β2-AR signaling in wound healing requires more investigation. Studies by Pullar et al.
have shown that β2-ARs could regulate migration and re-epithelialization of keratinocytes54, and that
blockade of β2-ARs increases keratinocyte migration. Antagonism of β2-ARs has many other effects
including enhancing angiogenesis, increasing secretion of vascular endothelial growth factor (VEGF) from
human keratinocytes, increasing the migration rate of human dermal fibroblasts (HDFs) in vitro, and
increasing expression of SM-α-actin, production of collagen III. Mice without β2-ARs have faster wound
healing, at least within the first few days post-injury55. Studies from the same group demonstrated that
antagonists of β2-AR could promote wound re-epithelialization by increasing phosphorylation and
activation of ERK signaling, increasing migration rate of keratinocytes, and increasing electric fielddirected migration. To conclude, blockade of β2-ARs with β-blockers appeared to be a promising strategy
for promoting skin wound healing (Figure 3.1)56.
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Figure 3.1 Schematic representation of interaction of the β2-AR
Agonists and antagonists in keratinocyte cell migration. Agonists of β2-AR inhibit directional migration
of keratinocytes while antagonists promote the migration, leading to increased wound repair. Reprinted
with the permission from Elservier [β-Adrenergic receptor modulation of wound repair] Volume 58,
Issue 2, August 2008, 158-164
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3.1.2

Drug: celiprolol

Celiprolol

is

a

relatively

cardio-selective

β1-adrenoceptor

blocker,

possessing

intrinsic

sympathomimetic activity, acting as a partial agonist on β2-receptors and having a direct vasodilator effect.
It is applied clinically for the treatment of mild to moderate level of hypertension57. Boutouyrie et al.
demonstrated that vEDS patients showed a decrease in the thickness intima to media. This decrease
resulted from the mechanical stress especially when the stress was against extremely fragile tissues14. They
postulated that treatment with celiprolol could decrease the mechanical stress which was loaded to the
arterial collagen fibrils coming from continuous and pulsatile pressure, ultimately preventing arterial
dissection and rupture. Following this publication, Ong et al. initiated a prospective randomized open
blinded-endpoint trial to systematically investigate the role of celiprolol in vEDS patients. Patients were
classified by their age (≤32 years or >32 years) randomly into two groups with an established and blinded
information. Fifty-three patients in this study were randomly grouped for either treatment with celiprolol
or as the control group. It is important to emphasize that at the initiation of the trial only thirty-three patients
had undergone genetic testing to confirm a mutation in COL3A1 gene. The dosage of celiprolol was
increased from100mg to a maximum of 400mg twice daily every six months. There was only 100mg for
each increase during the six months period. Primary endpoints were set to include rupture or dissection of
major arteries, and fatal or not. Results of this clinical trial showed that treatment of vEDS patients with
celiprolol reduced arterial events, such as rupture or dissection, three folds when compared with vEDS
patients in the control group. Thus, they recommended treating vEDS patients with celiprolol to prevent
major complications. However, the mechanisms by which celiprolol was effective at reducing arterial
events in vEDS patients was not determined6.
In the early wound repair process, myofibroblasts synthesize collagen III but was later replaced by
collagen I as the scars mature58. Studies by Pullar et al. showed that β2-AR antagonist treatment increased
the content of collagen III significantly in the wound area compared with no antagonist54. Xu et al. showed
that a stiffer arterial wall might result from an increase in the expression of type I as well as type III
collagen59. Celiprolol shows stronger β-1 selective activity compared with β2 agonist activity60 while Ong
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et al. showed an increased stiffness of arterial wall in their clinical patients after celiprolol administration6,
indicating that there was increased production of collagens in the arterial wall of vEDS patients after taking
celiprolol. Disrupted arterial wound healing and thrombus resolution after artificial injury were
demonstrated in chapter 2 of this dissertation. In conclusion, all the data suggested that celiprolol
administration might be able to induce the production of type III collagen to promote injury repair.

Hypothesis: we hypothesize that celiporolol administration in the Col3a1+/- mice would increase type III
collagen production after arterial injury and correct the aberrant injury repair in the Col3a1+/- mice.
Specific aims:
Celiprolol was used to treat both the Col3a1+/+ and Col3a1+/- mice and histology studies were performed
to compare the injury repair ability by detecting inflammation, cell proliferation and neovessel formation
in Col3a1+/- mice after celiprolol administration.

62

Figure 3.2 Flow chart of celiprolol trial
To modulate arterial injury repair in Col3a1+/+ and Col3a1+/- mice with celiprolol.
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3.2

Methods

3.2.1

Measurement of basic blood pressure for Col3a1 mice

The animal study protocol was approved by Animal Welfare Committee at UThealth at Houston. Mice
were surgically ligated at the left common carotid artery at the age of 12-14 weeks (unless otherwise stated)
and were weighed between 25 and 30g (same to that described in Chapter of this dissertation).
Experiments were carried out according to the flow chart (Figure 3.2). On day 1, basal blood pressure
was measured with the Kent Scientific CODA tail-cuff blood pressure machine (Kent Scientific
Corporation, CT). Mice were placed into the restraint tubes according to their weight and cuffs were placed
on the animal. They then were moved to the Animal Warming Platform that came with the machine and
the CODA cover was lifted to measure the tail temperature by pointing an infrared thermometer at the tail
base. The temperature was between 32°C and 35°C. The entire length of the animal’s tail rested on the
warming surface. Mice were measured with the machine for 3 consecutive days to get an average blood
pressure value. Mice were treated with celiprolol on day 3 (Friendly gift from Dr. Julie De Backer, M.D.,
Ph.D., Center for Medical Genetics, Ghent University Hospital, Belgium.) at a dose of 100mg/kg/day by
oral gavage delivery for 3 consecutive days. The drug was dissolved in purified water and the dosage was
determined in accordance with multiple studies61,5,62. On day six, blood pressure was measured again.

3.2.2

Carotid artery ligation and sample harvesting
The surgery procedure was modified from that described in Dr. Reid’s study (Amy Reid unpublished

data). Briefly, surgical mice were induced to anesthesia with 4% isoflurane which was maintained at 22.5% by a nose cone connected to the mouse. Aseptic techniques were used during the procedure and the
fur at the neck area was shaved off with Nair gel and sanitized with alcohol swabsticks. Afterwards,
analgesia with subcutaneous bupivacane (2.5 mg/kg) was applied immediately before making a midline
incision of 3mm in length in the neck with sterilized scissors. Followed by dissecting away the left common
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carotid artery from the carotid sheath and vagus nerve. A ligature was made on the artery with 6-0 silk
suture immediately at the bifurcation site where the internal carotid arteries separate from external carotid
arteries. It was important to be gentle to avoid bleeding. The open skin area was irrigated with iodine
alcohol and closed by 2 interrupted stitches with 5-0 suture which would be absorbed after about one week.
About 10% of animals experienced stroke symptoms of during the first 7 post-operative days (POD7).
Mice which failed to maintain 80% of their body weight were sacrificed. About 5% of the mice died before
ligation due to massive bleeding caused by the procedure of carotid artery dissection. Mice that did not
show neurological phenotypes such as stroke were monitored and treated subcutaneous with ketoprofen
(2-5mg/kg) twice a day for 2 days after surgery. They were weighed daily and injected mice as needed
with 0.5-1ml lactated Ringer's solution based on their weight for over 10% drops. Normally mice would
survive 95% after POD7. Mice were sacrificed on 7, 14 and 21 days after surgery for the different following
up experiments.

3.2.3

Histological Analysis: Morphology
For studies and analysis of POD7 arteries (N = 6 Col3a1+/+, 6 Col3a1+/-), POD14 (N = 6 Col3a1+/+,

6Col3a1+/-), and POD21 (N = 5 Col3a1+/+, 5 Col3a1+/-), mice were first sacrificed, followed by puncturing
of the left ventricles with a 27-gauge needle. An incision was made on the right atria to allow the outflow
of perfusate. Mice were then perfused with phosphate-buffered saline (PBS) at <20 ml/min until blanching
of the liver completely. Mice were then perfused with 10ml of 10% formalin at the similar rate to fix
arteries in the native geometry. Both the entire lengths of carotid arteries were harvested for multiple
experiments.
Arteries were followed by fixing in 10% buffered formalin for about 24 hours. After fixation, arteries
were cleaned up and the connective tissues were removed followed by processing. After processing, the
arteries were left in fridge to chill up. Then the arteries were cut three times with a scalpel: one cut was
immediate to the ligature to remove the suture; a second cut was at the location of the descending aorta to
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remove extra descending aorta; the third cut was in the mid-carotid artery. The remaining two pieces of
the artery were embedded with careful attention to maintain correct orientation. The entire block with
embedded artery was serial sectioned and three 5-µm-thick sections were collected per slide all through
the entire length of the arteries. Every tenth slide from the entire slides sequence was then performed with
hematoxylin and eosin (H&E) staining, followed by imaging a representative section on each slide. This
set of sequential images were enough for us to build up an entire arterial length along the axis of the arteries.
Each carotid artery could supply approximately 60 to 80 slides. All images in this dissertation were
presented at 20x, unless otherwise stated, and scale bars represent 100µm.

3.2.4

Immunohistochemical (IHC) staining
The IHC staining method was modified from Dr. Reid’s study (unpublished data) and most of the

methods were similar with only minor corrections. Briefly, each arterial segments as obtained above from
H&E-staining provided a relative location of each segment with neointima formation. Those unstained
slide neighboring each neointima positive slide was subjected to IHC probes (Mac-2, pH3 and CD31) to
investigate the amount of macrophages, the number of actively proliferating cells locate within the
neointima and the neovascularization in the medial layer. The first slide was probed with Mac-2, which
showed the number of macrophages. The second local slide was used to measure the number of pH3positive nuclei. The third slide was subjected to CD31 which was used to detect endothelial cells that are
precursors for neovessels. Unstained sections were processed before heat-induced epitope retrieval (HIER
citrate pH 6.0) followed by blocking for 1 hour at room temperature.
For detecting the local macrophages, slides with arterial sections were probed with rat anti-mouse
Mac-2 primary antibodies (Cedarlane, Burlington, NC) and incubated for 1 hour at room temperature. For
detection of proliferative cells, slides with arterial sections were probed with with rabbit anti-mouse pH3
primary antibodies (Millipore, Billerica, MA) followed by incubation overnight at 4˚C. To examine
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neovessel formation in formalin-fixed paraffin-embedded tissues, slides were left overnight at 4˚C with rat
anti-mouse CD31 antibodies (Dianova, Hamburg, Germany). Slides with arterial sections were then
washed with PBS, followed by incubation at room temperature for 1 hour with the appropriate biotinylated
secondary antibodies, and then tissues were probed with peroxidase-conjugated avidin/biotin complexes
(Vectastain ABC-AP Kit, Vector Laboratories, Burlingame, CA). Activity of peroxidase was detected
using a 3, 3’--diaminobenzidine (DAB) chromogen (Dako, Glostrup, Denmark). Slides were
counterstained with methyl green at the last step of staining.
For statistical analysis, slides were counted one by one to get the number of positive cells or vessels
independently. And then, for each genotype, a mean ±SD of positive cells was generated by averaging out
all the number from each group from the pooled neointima-positive slides, representing Col3a1+/+or
Col3a1+/-. Significant differences were determined by the Student's t-test between the means (*p < .05).

3.3
3.3.1

Results
No difference in basal systolic or diastolic blood pressure of Col3a1+/+ and Co3a1+/- mice
Celiprolol is known to have β2 agonist properties, and therefore blood pressure was assessed to

determine whether celiprolol lowers mouse blood pressure. We chose a dose of celiprolol based on studies
from rat, mice and human beings61,5,62. In these studies, dosages were between 50 to 200mg/kg/day for
mice or rats, but celiprolol was given to vEDS patients twice daily at doses from 100mg to 400mg. We
therefore chose of 100mg/kg/day for each mouse based on their body weight, a dosage that was
encompassed by both of these ranges. Blood pressure (BP) was measured before initiating the trial in 11
to 12-week-old mice. An average value of BP was generated by measuring on three consecutive days.
There was not a significant difference in the BP value between the Col3a1+/+ and Col3a1+/- mice at basal
level (Figure 3.3). Celiprolol was given for three days prior to carotid ligation, and BP was measured again
on post treatment day three (POT3), one day before ligation. In both genotypes, there was an average drop
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of 15mmHg in basal systolic BP after three days of celiprolol treatment; however, this result was not
statistically significant so we cannot conclude that celiprolol lowers blood pressure in mice.
We were curious whether celiprolol might be effective in lowering BP after a longer period of
treatment. Therefore, BP value was measured a third time, at POD14 (data not shown) and POD21 (post
treatment day 24 (POT24)), immediately before harvesting arteries (Figure 3.3). However, there was no
dramatic difference in the BP value after celiprolol administration for 24 days either.

Figure 3.3 Comparison of the systolic blood pressure after celiprolol administration
Data representing 3 post days of treatment (POT3) and 24 days post treatment
(POT24) in Col3a1 mice, NS indicating no significant difference.
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3.3.2

Decreased neointimal layer formation in Col3a1+/- mice carotid arteries after celiprolol
treatment
As proposed in Chapter 2, to determine if celiprolol corrected the arterial injury repair process in the

Col3a1+/- mice, neointima formation was first examined by H&E staining. Since there were only
significant differences in pathological changes at POD14 and POD21 when comparing Col3a1+/+ and
Col3a1+/- mice at basal level, we only looked at these timepoints after celiprolol treatment. Compared with
arteries from mice without celiprolol treatment, there was decreased neointima formation in arteries from
both Col3a1+/+ and Col3a1+/- mice with celiprolol treatment at both POD14 (POT17) and POD21 (POT24)
as shown in (Figure 3.4).

Figure 3.4 Remodeling of neointimal by H&E staining after celiprolol administration
Representative sections of the Col3a1+/+ and Col3a1+/- mice both without (top panel) and with
celiprolol treatment (bottom panel), showing decreased neointima formation after celiprolol
treatment in mice from both groups at both POD14 and POD21. Scare bar: 100μm.
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3.3.3

Altered cell proliferation and inflammation in the neointimal layer after celiprolol
treatment
We further stained the arterial sections with anti-pH3 antibody to detect the cell mitosis marker pH3,

which indicated the proliferative cells in the neointima. There were decreased pH3 positive cells in the
arteries from celiprolol treated Col3a1+/- mice compared with arteries from untreated Col3a1+/- mice
(Figure 3.5a). No significant difference in pH3 positive cells was observed comparing Col3a1+/+ arteries
from no celiprolol and celiprolol treated mice at both POD14 and POD21 (Figure 3.5b). This result
indicated that celiprolol was more effective in decreasing cell proliferation in the arteries from Col3a1+/mice than in the arteries of Col3a1+/+ mice.
It was shown by Rough et al. that β2-AR blockade could decrease the hyper-inflammatory reaction
after traumatic injury in mice63. To look at the inflammation level at the neointima after celiprolol
administration, IHC with anti-Mac-2 antibody was used to detect the number of macrophages in the
neointima (Figure 3.6a). At basal level, prior to celiprolol treatment, there were significantly more Mac2 stained cells in Col3a1+/- arteries compared with arteries from Col3a1+/+ mice at both POD14 and POD21
(Figure 3.6b). However, after celiprolol treatment, a significant decrease was observed after analyzing
Mac-2 positive cells in Col3a1+/- arteries comparing with those from untreated Col3a1+/- arteries (Figure
3.6b). No difference was observed for Mac-2 stained cells when comparing Col3a1+/+ arteries from no
celiprolol and celiprolol treated mice at both POD14 and POD21. Again, results showed that celiprolol
was more effective in lowering inflammation level in the arteries from Col3a1+/- mice.
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Figure 3.5 Decreased cell proliferation in Col3a1+/- arteries after celiprolol administration
(a) Representative sections of arteries from both Col3a1+/+ and Col3a1+/- mice, both without (top
panel) and with (bottom panel) celiprolol treatment, (b) Higher power images, red arrow showed
the neointimal pH3 positive cells, (c) Quantitation showed significantly decreased number of pH3
positive cells after celiprolol treatment in arteries from Col3a1+/- mice at both POD14 and POD21
indicating decreased cell proliferation in the Col3a1+/- arteries after celiprolol treatment. NS: no
significance, **p<0.01，***p<0.001 by Student’s t-test.
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Figure 3.6 Decreased neointima inflammation in Col3a1+/- arteries after celiprolol
administration
(a) Representative sections of arteries from both Col3a1+/+ and Col3a1+/- mice, both without (top
panel) and with celiprolol treatment (bottom panel) (b) Higher power images, red arrow was showing
the neointimal Mac-2 positive cell (c) Quantitation showed significantly decreased number of Mac-2
positive cells after celiprolol treatment in arteries from Col3a1+/- mice at both POD14 and POD21
indicating decreased inflammation in the Col3a1+/- arteries after celiprolol treatment. NS: no
significance, **p<0.01, ***p<0.001 by Student’s t-test.

72

3.3.4

No difference in the formation of new vessels in the medial layer after celiprolol treatment
at both POD14 and POD21
Similarly, IHC with anti-CD31 antibody was used to detect the presence of CD31 for assessing the

formation of neovessels in the medial layer after administration of celiprolol. At basal level, when there
was no celiprolol treatment, there were significantly more CD31 positive neovessels in the arteries from
Col3a1+/- mice compared with those from Col3a1+/+ mice at both POD14 and POD21 (Figure 3.7a).
However, after celiprolol treatment, no significant difference was found in the formation of neovessels
comparing arteries from Col3a1+/+ mice with those from Col3a1+/- arteries. There was also no statistical
difference between the number of neovessels in Col3a1+/- arteries treated with or without celiprolol. These
results indicated a potential partial blunting of neovessel formation in Col3a1+/- mice with celiprolol
treatment, but more studies need to be done to confirm the role of celiprolol in affecting neoangiogenesis.
(Figure 3.7b).
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Figure 3.7 No significant difference in neovessel formation after celiprolol
administration
(a) Representative sections of arteries from both Col3a1+/+ and Col3a1+/- mice, both without (top
panel) and with celiprolol treatment (bottom panel) (b) Higher power images and red arrow was
showing medial layer neovessel by CD31 staining (c) Quantitation showed no difference in the
potential of new vessel formation in both mice genotypes after celiprolol treatment. NS: no
significant difference by Student’s t-test.
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3.4

Discussion
To better understand the mechanisms leading to vEDS and to discover a possible therapeutic approach

for vEDS patients, previous work of Dr. Reid (unpublished data) and studies in the first part of Chapter 2
of this dissertation were conducted which showed a consistent defective in injury repair in Col3a1+/- mice
compared to that in Col3a1+/+ mice. These results confirmed a defect of injury repair in the Col3a1+/- mice
when there was not sufficient type III collagen. This suggested that there was aberrant injury repair in
vEDS patients, resulting in both aberrant skin wound healing and also problems with arterial injury repair
causing frequent arterial events such as dissection or aneurysms of vEDS patients and leading to a
decreased life expectancy for these patients64.
Ong et al. speculated that patients taking celiprolol would have alleviated high blood pressure in
hypertensive people which could lead to a decreased in stress formed against arterial collagen fibers
resulting in decreased incidence of arterial dissections and ruptures, and showed that taking celiprolol, a
β-blocker, could decrease the arterial events in vEDS patients threefold6. They initiated a clinical trial to
investigate the effects of celiprolol on vEDS patients. Instead however, their findings proved that celiprolol
could have demonstrated more stable haemodynamic resistance which lead to a more strenuous arterial
wall. Data generated from this current study did not show the effect of celiprolol to lower blood pressure
at both 3 days and 24 days after administration, which was consistent with the discoveries by Ong et al.
However, we could not conclude that celiprolol did not show β2 agonist activity in this study due to absent
data from a critical group-regular ligation without celiprolol treatment, as the ligation procedure itself
might have lead to an increase in systematic blood pressure.
Inflammation following arterial injury plays a critical role in both cutaneous and arterial injury
repair20. Secretion of TGF-β by macrophages and platelets would induce the differentiation of
myofibroblasts from fibroblasts both of local origin and from bone marrow derived (BMD) fibrocytes37.
After the expression of type III collagen by myofibroblasts, contracting cells would pull open the fibrin
clot resulting in successful thrombus resolution after arterial injury. Unpublished data from our laboratory
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has shown a significant increase in inflammation of POD14 and POD21 arteries in the Col3a1+/- mice
without celiprolol treatment, compared with that in the Col3a1+/+ mice in the neointima layer (p<0.05).
Morissette et al. harvested both plasma as well as dermal fibrobalsts from vEDS patients and
investigated the role of inflammation and the expression of proteins for TGF-β pathways65. They
demonstrated that vEDS patients usually have a chronic inflammation going on all through their life.
Results from the pathological data of the current study also showed that there was decreased inflammation
in the neointima in the Col3a1+/- arteries after ligation indicating the potential of Col3a1+/- mice in
repairing arterial injury after celiprolol treatment.
Other studies have shown that celiprolol was effective in cardiovascular diseases effects through the
antioxidative properties to increase the function of vascular endothelial progenitor cells (EPCs), resulting
in a decreased intimal thickening after vascular injury66.67. Previous data showed in Chapter 2 of this
dissertation that there was an increase in the potential of cell proliferation POD14 and POD21 with carotid
injury in the Col3a1+/- mice when comparing to that in the Col3a1+/+ mice in the neointimal layer. However,
after treating both groups of mice with celiprolol, a dramatic decrease was observed in cell proliferation in
injured Col3a1+/- arteries with celiprolol treatment compared with that of no celiprolol injured Col3a1+/arteries (Figure 3.7). Yao et al. also showed the decreased proliferative cell activity in the vein graft
neointima after celiprolol administration66, which was consistent with data from the current study.
However, we were not able to determine the mechanism beyond the pathological change with celiprolol
administration.
From our unpublished study, there was dramatic neovessel formation in the medial layer after carotid
injury at both POD14 and POD21 in Col3a1+/- mice, compared to that in Col3a1+/+ mice in the medial
layer. This neovessel formation may to predispose arteries to fragility, resulting in dissection and arterial
rupture. We sought to use celiprolol to modulate the thrombus resolution and neovessel formation
procedure in the Col3a1+/- mice, we didn’t get any difference in neovessel formation in the media with
celiprolol treatment. Although the neovessel data is inconclusive, we were able to decrease the
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inflammation and cell proliferation in the Col3a1+/- mice. Though there were limitations for the current
study in that no cellular/molecular work has been done to prove why and how celiprolol does these things.
Pullar et al. concluded that β-adrenergic receptor modulation of wound repair through a variety of
signaling pathways by both in vivo and in vitro models50,56 (Figure 3.1). As with their studies, future studies
should be focused on investigating the role of celiprolol on inflammatory responses and cell proliferation
by in vitro models. Cells should be explanted from Col3a1+/+ and Col3a1+/- mice to understand the
cellular/molecular mechanisms and explain the data generated from the current study.
In conclusion, celiprolol was effective in decreasing the inflammation and persistent cell proliferation
in the neointima of the Col3a1+/- arteries but not in decreasing the neovessel formation in the medial of
those arteries. Indicating that it might be used to alleviate the symptoms of vEDS patients.
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4

Dysregulated Myofibroblasts from Col3a1+/- Mice Contribute to the Abnormal Injury Repair
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4.1
4.1.1

Introduction
Myofibroblasts in wound healing
Characteristics of vascular Ehlers-Danlos Syndrome (EDS) include thin, translucent, and often,

bruised skin. This easy bruising indicates aberrant injury repair in vEDS patients64. Myofibroblasts are key
players in normal injury repair37. After a tissue has been wounded, myofibroblasts are involved in a few
events in remodeling tissues68: (1) secretion of ECM proteins (2) tension sensation and transduction and
(3) apoptosis, through which they disappear from the wounding area.
Myofibroblasts are differentiated from fibroblasts demonstrated by the expression of α-SMA, which
is one of the major mechanosensitive proteins that is recruited to stress fibers under high mechanical stress.
With the expression of α-SMA, myofibroblasts gain highly contractile potential69. Myofibroblasts can not
only produce procollagen type I and III, but also other ECM components, such as collagens70. With the
expression α-SMA, myofibroblasts assemble bundles of contractile microfilaments that stretch across the
cell and attach to different cell surface protein complexes that link the intracellular filaments to the
surrounding area of extracellular matrix (ECM)71.
Secondly, contraction of myofibroblasts is accomplished by the motor mechanism of the myosin head
domain sliding along the actin filaments, and this sliding mechanism creates a tension that is transferred
to the surrounding ECM70. An extended network of stress fibers results in the formation of large focal
adhesion sites, also called super-mature focal adhesions (FAs)72. The size of the FAs is critical to control
differentiation and contracture of myofibroblasts69.
Lastly, after wound closure, myofibroblasts undergo automatic cell apoptotic procedure and disappear
gradually from the site of injury. Normal procedure of myofibroblasts apoptosis results in formation of
scar from granulation tissues while abnormal apoptosis leads to the development of pathological scarring73.
This balance ensures to tissue integrity31. Disturbances such as abnormality in tissue contraction to
excessive deposition of ECM, could severely impair skin function. Common problems include
hypertrophic scar formation, scleroderma, skin contractures after a burn73. Fibrosis in the in the kidney,
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heart or lung also rely on these same cells functioning in the same way, but pahologically21. It is promising
that many studies suggest that myofibroblasts are bone marrow-derived (BMD), as perhaps modulating
the bone marrow could address many of these health problems37.

4.1.2

Role of TGF-β in differentiation of fibroblasts and arterial injury
TGF-β1 is a cytokine secreted by platelets, fibroblasts and macrophages. Injection of TGF-β1 to rats

subcutaneously resulted in a granulation tissue formation in which there are particularly abundant amount
of myofibroblasts with α-SMA expressing while injection of other growth factors or cytokines such as
TNF-α or PDGF did not induce α-SMA expression in myofibroblasts74. This suggests the importance for
TGF-β1 in myofibroblast differentiation in the procedure of wound healing and fibro-contractive diseases
by the regulation of α-SMA expression in those cells. A study from James et al. also demonstrated that
TGF-β1 played a significant role in cutaneous wound repair: wounds were made by an incision on the skin
of a pig and expression of TGF-β1 and integrin was examined. Expression of TGF-β1 within the
extracellular matrix area was finely coordinated with an increased expression of different integrin
subunits75. Thus, they concluded that in the different steps of wound repair procedure, TGF-β1 could
induce the expression of integrins by epidermal keratinocytes to facilitate the migration for reepithelialization.
In the classical TGF-β signaling, three different isoforms of TGF-β ligands are believed to bind two
TGF-β receptors (TβRI and TβRII) through which signal is transduced (Figure 4.1). TβRII is constitutively
phosphorylated and they phosphorylate TβRI once bind to the ligand. Once phosphorylated, the ligand and
receptor complex will activate the intracellular SMAD signaling pathway. The SMAD proteins will then
be translocated to the nucleus for regulation of other targets genes22.
Studies by Roberto et al. proposed that TGF-β1 secreted by macrophages and platelets at sites of
injury would not only recruit fibroblast but also induce the differentiation of them to form myofibroblasts.
Formation of myofibroblasts ensures the production of major ECM components such as collagens and the
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contraction to close the wound76. Taken together, these studies and others showed that TGF-β1 is one of
the key players in modulating the wound healing process described above, in part by regulating the function
of myofibroblasts.

Figure 4.1 Summary of TGF-β signaling in hypertrophic scarring
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4.1.3

Focal adhesions (FAs) and focal adhesion kinase (FAK) in the differentiation of fibroblasts
Focal adhesions are located at the convergence of integrin receptors. They transduce signal to other

cell adhesions and actin cytoskeleton72. They are within the site where integrin receptors and proteoglycan
attach to cytoskeleton formed by actin. According to the subcellular location, composition and size, focal
adhesions are mainly classified into four different groups: focal adhesions, focal complexes, threedimensional (3D) matrix adhesions, and fibrillary adhesions77.
Thannickal et al. showed that in addition to TGF-β1, myofibroblast phenotype was dependent on
adhesion-dependent signals23. Increased expression of α-SMA is first activated by TGF-β signaling and
followed by FAK signaling pathway. In this study, they demonstrated that both TGF-β1 and adhesiondependent signals were required for a stable expression of the myofibroblast phenotype. TGF-β1-induced
myofibroblast differentiation would be inhibited in non-adherent cells even if the existence of TGFreceptor-Smad2 phosphorylation signaling. Tyrosine phosphorylation of FAK induced by TGF-β1 which
including Tyr-397 was also delayed in relative to early TGF-β1-Smad signaling. Blockage of FAK or
induced expression of kinase-mutated FAK, inhibited expression of α-SMA as well as stress fiber
formation and cellular hypertrophy induced by TGF-β1. Their working model was illustrated in Figure
4.2.

4.1.4

MRTFA and fibroblasts differentiation
Myocardin-related transcription factor-A (MRTF-A) and -B (MRTF-B) are widely distributed. Both

of them interact with G-actin and are sequestered in the cytoplasm78,79. Once there is stress, the actin
dynamics would be altered for the formation of F-actin fibers and further enhance nuclear MRTFs
accumulation80. Within nuclear, SRF/MRTF binding together to form a complex which specifically binds
to short element of CArG locating within the promoters of contractile related genes. Smooth muscle αactin (SMA, ACTA2) and transgelin (TAGLN, SM22) are the two genes most responsive to stress81. Thus,
MRTFs play a critical role for SMCs to respond to stress. It was also shown that MRTFA contributes to
myofibroblast differentiation and contractility82.
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Figure 4.2 Schematic of the proposed regulatory pathways involved in
myofibroblast differentiation.
TGF-β receptor(s) signaling is primarily mediated by rapid phosphorylation/activation of Smad
proteins, which occurs by an adhesion-independent mechanism. Other unidentified non-Smad
pathways may also be activated early post-TGF-β receptor(s) activation. FAK
autophosphorylation/activation is delayed relative to Smad signaling and is associated with
TGF-β1-induced expression of both integrin subunits and fibronectin/collagens. Integrin
signaling via FAK autophosphorylation/activation is essential for induction/maintenance of the
stably differentiated myofibroblast phenotype. With permission from American Society for
Biochemistry and Molecular Biology.
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Studies with fibroblasts from Col3a1+/- mice and unpublished data on mice embryonic

4.1.5

fibroblasts (MEF) and fibroblasts from vEDS patients
Studies by Volk et al. showed that deficiency of type III collagen promoted differentiation of
myofibroblast and increased scar formation after cutaneous wounding. They showed that aged Col3a1+/mice had was quicker in wound healing comparing with Col3a1+/+ mice using an in vivo wounding model.
Wounds were made on both Col3a1+/+ and Col3a1+/- mice, and wound area (WA) was measured at
different time points. By using fibroblasts explanted from Col3a1+/+ and Col3a1+/- mice skin tissues, they
demonstrated that Col3a1+/- mice showed increased ability in wound closure compared with that of
Col3a1+/+ mice83. The in vitro data showed that fibroblasts from Col3a1+/- and Col3a1-/- mice express more
α-SMA compared with cells from Col3a1+/+ mice by immunofluorescent staining (Figure 4.3). In
conclusion, their study demonstrated that a type III collagen was importantin modulating myofibroblast
differentiation and activity during cutaneous repair. They also identified a possible mechanism in vivo for
an increased scar formation in wounded Col3a1 deficient skin. Unpublished in vitro data from Dr. Reid
showed dysregulated fibroblasts in the Col3a1+/- mice by increasing expression of α-SMA, increasing
collagen I fibril formation in 3D fibrinogen gel experiment. Finally, results from Chapter 2 in this
dissertation demonstrated that BMD fibrocytes were critical in the correction of injury repair in Col3a1+/mice.

SMCs：
As we discussed in chapter 2, introduction section that SMCs migrating from arterial wall contribute
to the neointima formation followed by thrombus resolution39.
Hypothesis
Taken together, we hypothesize that myofibroblasts from the Col3a1+/- mice predispose a persistent
differentiated status due to the defects in contracture, leading to an aberrant wound healing in the Col3a1+/mice after arterial injury. To address the hypothesis, fibroblasts from mouse lungs were explanted
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according to protocol adapted from Dr. Blackburn’s laboratory, and in vitro studies were performed with
the fibroblasts. SMCs were explanted from the ascending aorta of Col3a1+/- mice84.

Specific aims:
1. Is there any difference in phenotype between Col3a1+/+ and Col3a1+/- fibroblasts/myofibroblasts?
a)

Test the myofibroblasts differentiation and compare if there is any difference between Col3a1+/+
and Col3a1+/- fibroblasts by detecting the expression of RNA and protein for SMC markers,
collagens and integrins.

b)

Examine the formation of F-actin of fibroblasts by actin IF staining and F/G actin assay.

2. Is there any difference in phenotype of Col3a1 SMCs?
a)

Expression of RNA and protein for SMC markers, collagens and integrins.

b)

Test the potential of SMC proliferation by BrdU assay, MTT assay.

c)

Examine the formation of stress fiber by F-actin IF staining.

3. Why there is the difference between cells explanted from both Col3a1+/+ and Col3a1+/- cells? Is
there any focal adhesions link collagen and actin expression/polymerization in both, is there any
difference?
a)

Focal adhesion staining by vinculin IF

b)

Focal adhesion signaling to detect activity of pFAK by both Western blots and IF staining
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Figure 4.3 Increased α-SMA expression by Col3+/– and Col3–/– cells compared to Col3+/+ cells
Cells from all 3 genotypes, utilized in the attached fibroblast-populated collagen gel assay, were
immune-stained for α-SMA (green) and counterstained with DAPI (blue). Collagen lattices
seeded with cell isolates from at least 3 embryos per genotype were analyzed. a Myofibroblasts
within collagen lattices were identified by α-SMA expression. α-SMA incorporation into stress
fibers (arrows) could be visualized in cells from all 3 genotypes. b-d Representative images
showing the percentage of myofibroblasts in cultures of Col3+/+ (b), Col3+/– (c), and Col3–/–
(d) . Copyright (1997) National Academy of Sciences, U.S.A
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4.2

Methods

4.2.1

Fibroblast explant from mouse lung tissues
To explant fibroblasts, mice were sacrificed humanely at 4-6 weeks. Mouse was then perfused with

10ml cold-sterile PBS at the right ventricle, the whole lung tissues were taken out and put into a clean
petri-dish with PBS. Then tissues were rinsed to remove blood cells, cleaned up to remove connective
tissues and brought to tissue culture hood. The tissues were rinsed with 70% ethanol and PBS followed by
cutting into very small pieces (0.1-0.5mm) with an autoclaved blade. Small pieces of lung tissues were resuspended with 10ml PBS and transferred to 75mm2 flask. PBS was aspirated and the tissues were left to
attach to the bottom of the flasks, followed by leaving the flasks vertically in the incubator for 2 hours.
After incubation, extra PBS was aspirated from the bottom of the flask followed by adding10ml high
glucose DMEM with 10% FBS and 1% antibiotics. Leave the flasks incubated for 14 days and media was
changed very other day. Cells were split from one T75 flask to two T75 flasks when they were about 8090% confluence and labelled as passage 1(P1). Experiments were set up for harvesting protein, RNA,
immunofluroscent (IF) and BrdU samples with cells which were at 90% confluence and less than P4.
Two independent cell lines were generated from Col3a1+/+ and Col3a1+/- mice, using lungs pooled
from two mice for each genotype per explant. Results presented in this dissertation were representative of
two independent experiments replicated on each line of fibroblasts. Fibroblasts used in this study were
passage- and sex-matched explanted from Col3a1+/+ and Col3a1+/- mice. Fibroblasts were used at no more
than passage 3.

4.2.2

Isolation of Vascular SMCs from Col3a1+/+ and Col3a1+/- mice

4-6-week old Col3a1+/+ and Col3a1+/- mice were used for isolating mouse aortic SMCs according to
the protocol developed by our lab84. Briefly, aortas were pooled from at the aortic root and up until the
bifurcation of the renal artery. Whole aortas collected were treated under sterile techniques and transferred
to media for collecting biopsy. (Table 1). Ascending aorta was collected from each mouse. Followed by
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removing the connective tissues. The aorta was washed and then cut into 1mm pieces. All the aortic tissues
were collected and put into digestion medium for 16 hours. The medium was prepared as shown in Table
1. Followed by spinning down cells and small tissues. Cells and tissue pallets were then re-suspended in
complete SMC medium and put into petri-dishes for another 14 days of incubation. The expression of αactin was used to define the cell identity explanted.
Two lines of fibroblasts from Col3a1+/+ and Col3a1+/- mice were generated independently, using
aortas pooled from four mice for each genotype per explant. The results presented in this study were
representative of two independent replicates. Passage-and-sex-paired SMCs from Col3a1+/+ and Col3a1+/mice were used at no more than passage 4 for all the experiments.
Table 1 Media and buffer used in this project

4.2.3

Isolation of RNA and q-PCR
RNA extraction kit (Invitrogen, Carlsbad, CA) was used to collect entire cellular RNA. Briefly, RNA

lysis buffer with 1% β-Mercaptoethanol was prepared, cells cultured in 6cm petri-dish were washed with
PBS for 2 times. 700ul lysis buffer was put into each petri-dish and incubated at 4ºC or on ice for 30
minutes. The mixture was transferred to 1.5ml eppendorf tube, thoroughly mixed with 21gauge syringe
for 10 times, followed by adding 0.7 volume 70% ethanol and vortexing to mix thoroughly. The mixture
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was transferred to the mini-column with the kit, spun down at 12,000 rpm for 15 seconds, the column was
washed 3 times before adding 30-100ul sterile water to dissolve RNA on the column. The concentration
of the samples was between 100-300ng/ul. IScript supermix kit (Bio-rad laboratories, Hercules, CA) was
applied for reverse transcription directed by protocol from the manufacturer. Q-PCR analysis was applied
for target genes expression with TaqMan probes. TaqMan probes for target genes were purchased from
Applied Biosystems and results of q-PCR was analyzed with an Applied Biosystems Prism 7900 HT
Sequence Detection System (Applied Biosystems, Foster City, CA) using the manufacture’s protocol.
Results were generated by three independent times. Endogenous control was referred to the expression of
Gapdh. Data was analyzed by 2-ΔΔCT method to generate a p-values Student’s t-test.

4.2.4

Protein preparation and Western blotting
Cells cultured in 6cm petri-dish were washed 2 times with PBS. After washing, 120ul cell lysis buffer

for western blot was added to each petri-dish then lysed cells cultured in petri-dish. Samples were
incubated at 4ºC in fridge or on ice for 30 minutes and followed by manually vortexed 3 times. Supernatant
was collected and then quantitated by a Bradford assay. After quantitation, equal amount (5ug or 10μg) of
protein was prepared and loaded onto 4-20% protein gels (Bio-Rad laboratories, Hercules, CA). A standard
way of western-blotting in this laboratory was used. Briefly, membranes with complete proteins from SDS
page gel were put into 5% non-fat milk blocking buffer for 1 hour. After blocking, the membranes were
probed with appropriate primary antibodies, usually 1:1000 dilution in 5% TBST/milk buffer followed by
washing before probing with appropriate secondary antibodies, usually 1:5000 dilution in 5% TBST/milk
buffer. See Table 2 for information of antibodies. Immunoblots were developed to see the expected bands
of target proteins using regular or enhanced chemiluminescence technique (GE Healthcare, Piscataway,
NJ).
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Table 2 Antibody information

4.2.5

Cell proliferation assay
5,000 cells (Mice lung fibroblasts or SMCs) were put in a 96-well plate and incubated 20-24 hours

before serum-starvation with DMEM containing 1% FBS. After starving 24 hours, TGF-β1 (2 ng/mL)
was added and kept for 24 hours before addition of BrdU reagent to each well and incubating for 24 more
hours. BrdU ELISAs assay was performed with the instruction from the manusfacture (Millipore, Bedford,
MA.) BrdU ELISA assay was applied in replicates. p*<0.05 using Student’s t-tests was generated as
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statistical significance.

4.2.6

TGF-β1 administration to fibroblasts and immunofluorescent staining (IF)
Fibroblasts or SMCs were seeded onto 18mm glass coverslips. And about 5,000 cells suspended in

complete media were seeded on a single coverslip. Cells were starved with 1% FBS media after incubation
for 20-24 hours. Fresh media containing 1% FBS with TGF-β1 (2ng/mL) was used to replace the starvation
media. 4% paraformaldehyde (PFA) was added to fix cells after 72 hours TGF-β1 induction. For focal
adhesion staining, PBS with 0.2% saponin and 10% FBS was applied to permeabilize cells on coverslips,
which were incubated at room temperature for 10 minutes before blocking in PBS with 5% donkey serum
for 30 minutes. Coverslips were then probed with vinculin antibody (1:200, Sigma-Aldrich, St. Louis, MO)
at 4ºC overnight. The following day, coverslips were washed before adding Vectashield mounting medium
with DAPI (Vector Labs, Inc., Burlingame, CA). Then nail polish was used to seal coverslips which were
then stored in cold room until they were taken out for images. Table 1 provides information of the
antibodies used.
Analysis of Immunofluorescence Images
For vinculin staining and pFAK staining, images were obtained on Olympus Fluoview 300 confocal
microscope using a PL APO LSM2 40x water immersion objective with NA=0.9. The image statistics and
masking tools coming with the SlideBook software (Intelligent Imaging Innovations, Denver, CO) were
used to measure area of cell and focal adhesions. To compare sufficient cell number, area of vinculin
staining and focal adhesions was normalized to each total cell area of each cell followed statistical analysis.
A p < 0.05 was generated by the Student’s t-test and was determined as significant difference.
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Figure 4.4 Expression level of contractile proteins
RNA was isolated from both TGF-β1 treated and control cells at different time points.
qPCR was performed according to the protocol, statistics was generated by Student’s t
test and *p<0.05, NS: no significance.

92

4.3
4.3.1

Results
Both the Col3a1+/+ and Col3a1+/- fibroblasts respond to stimulation by TGF-β1
At the injury site, immediately after thrombi formation, there is increased secretion of TGF-β1 by

platelets and activated macrophages46, resulting in a TGF-β1 rich environment. TGF-β1 is widely accepted
as a chemokine that promotes differentiation of myofibroblasts from fibroblasts as assayed by expression
of contractile proteins. To examine the differentiation of fibroblasts, in vitro experiments were conducted
by examining the expression of contractile proteins with fibroblasts explanted from mouse lung tissues.
Expression of three most common contractile proteins, Acta2 (SM-actin), Cnn1 (calponin), and SM22
(transgelin) were detected. Both Acta2 and SM22 genes were expressed at significantly higher levels after
24 hours of TGF-β1 treatment (Figure 4.4a). But Cnn1 gene was only expressed significantly higher in
the Col3a1+/- cells. The expression of all the contractile proteins decreased at 48 hours. We next examined
their protein accumulation by westernblot. Interestingly, there was increased expression for all three
proteins after 48 hours of TGF-β1 treatment and persistent up until after 72 hours in Col3a1+/- cells (Figure
4.4b). The results indicating stable increased protein accumulation of contractile targets in the Col3a1+/fibroblasts after TGF-β1 treatment.
We then examined the expression of collagens genes, Col1a1, Col1a2 and Col3a1 as well as collagen
receptors, Itga2 and Itgb1 (Figure 4.5a). There was not any significant difference between Col3a1+/+ and
Col3a1+/- cells after TGF-β1 for either 24 or 48 hours for both Col1a1 and Col1a2, but there was significant
decreased expression of Col3a1 in Col3a1+/+ cells after 24 hours treatment.
There was significant less Itga2 expression in Col3a1+/- cells compared to that in Col3a1+/+
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cells at basal level while expression of Itga2 decreased dramatically in Col3a1+/+ cells after 48 hours. And
there was significantly increased expression of Itgb1 in Col3a1+/- cells compared to that in Col3a1+/+after
both 24 and 48 hours treatment (Figure 4.5b).

Figure 4.5 Expression of collagens (a) and two collagen receptors(b)
RNA was isolated from both TGF-β1 treated and control cells at different time points. qPCR
was performed according to the protocol, statistics was generated by Student’s t test and *p
<0.05, **p<0.01, NS: no significance.
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4.3.2

More formation of stress fibers in Col3a1+/- cells at basal level but not after TGF-β1
stimulation
To validate the more differentiated status of Col3a1+/- cells after TGF-β1 stimulation, we performed

IF staining to examine the F-actin polymerization in both Col3a1+/+ and Col3a1+/- fibroblasts (Figure 4.6).
It was shown that both Col3a1+/+ and Col3a1+/- cells significantly expression more a-actin, but in Col3a1+/cells, a-actin were not assembled into F-actin fibers normally.

4.3.3

Significantly increased activity of focal adhesion signaling in the Col3a1+/+ cells after TGFβ1 stimulation for 72 hours
Focal adhesions (FAs) are widely distributed at the plasma adjacent to the membrane area and to

sense forces against cells. Size of FA and maturation of them has been shown to demonstrate the degree
of myofibroblasts differentiation72. We then asked whether the FAs in Col3a1+/- cells might be more mature
compared to those from the Col3a1+/+ cells. Vinculin is one of the components of FAs and has been used

Figure 4.6 Abnormal actin polymerization in Col3a1+/- myofibroblasts
Abnormal actin polymerization in Col3a1+/- fibroblasts after treatment with TGF-β1 for 72hrs.
Images are from IF staining showing merge of a-actin (green), DAPI (blue) and F-actin (red).
as a marker of FAs. IF of vinculin was used to show the size and location of focal adhesions. Results
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showed an increase in area of vinculin/area of cell in Col3a1+/- comparing with that in Col3a1+/+ fibroblasts
at basal level, but there was significant increase in vinculin area/cell area in Col3a1+/+ cells compared with
that in Col3a1+/- cells with 72 hours TGF-β1 induction. (Figure 4.7a), indicating the size of FAs in the
Col3a1+/-cells was not increased after TGF-β1 treatment.

4.3.4

No activation of pFAK in in vitro tissue culture of Col3a1+/- fibroblasts
Focal adhesion kinase (FAK) locates at FAs and function as a protein to transduce signaling. A group

of different signaling pathways are activated by FAK, such as MAPK and PI3K-AKT. Activity of FAK
was assayed to determine if there was increased kinase activity in the Col3a1+/- fibroblasts. Western blot
analyses showed that there was not significant difference in phosphorylation of FAK comparing Col3a1+/+
cells to Col3a1+/- cells after TGF-β1 treatment (Figure 4.7c). However, immunofluorescent staining (IF)
of pFAK revealed a smaller pFAK area/cell area in Col3a1+/- cells compared with Col3a1+/+ cells at both
basal level and after TGF-β1 treatment for 72 hours (Figure 4.7b). This indicated that Col3a1+/- cells were
not further responding to TGF-β1 compared to Col3a1+/+ cells.
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4.3.5

Increased translocation of MRTFA into the nucleus of Col3a1+/- myofibroblasts

Figure 4.7 Altered focal adhesions in both Col3a1+/+ and Col3a1+/- cells
(a) Immunofluorescent staining (IF) to detect vinculin, marker for focal adhesions, results
showed an increase in vinculin area/cell area in Col3a1+/- cells compared to that in Col3a1+/+ at
basal level, but there is significant increase in vinculin area/cell area in Col3a1+/+ cells compared
with that in Col3a1+/- cells after TGF-β1 treatment for 72 hours (b) IF to detect pFAK results
showed that there was increase in pFAK area/cell area in Col3a1+/+ cells compared with that in
Col3a1+/- cells at both basal level and after TGF-β1 treatment for 72 hours. Cells were treated
with TGF-β1, followed by IF staining, and images were obtained on Olympus Fluoview 300
confocal microscope using a PL APO LSM2 40x water immersion objective with NA=0.9.
Significance was evaluated at p *< 0.05.

MRTFA which was shown to be responsible TGF-β1 induced myofibroblasts differentiation by
multiple studies82. In order to find out the reason for the differentiation of Col3a1+/- fibroblasts, we
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conducted IF staining of MRTFA with Col3a1+/+ and Col3a1+/- fibroblasts with 72-hour TGF-β1 induction
to determine the translocation of MRTFA from cytoplasma to nucleus. Quantitation was done by
measuring the intensity of the staining. Result showed the increased MRTFA intensity in the nucleus of
Col3a1+/- cells compared with the Col3a1+/+ cells (Figure 4.8), indicating that after stress exposed to
fibroblasts, Col3a1+/- cells were more dependent on MRTFA signaling to further drive differentiation
instead of FAK signaling.
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Figure 4.8 Increased translocation of MRTFA into the nucleus of Col3a1+/- myofibroblasts
Immunofluorescent staining (IF) to detect MRTFA, marker for focal adhesions, results showed that
there was an increase in translocation of MRTFA in Col3a1+/- cells compared to that in Col3a1+/+
cells after TGF-β1 treatment for 72 hours. Significance was evaluated at *p < 0.05.
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4.3.6

Increased differentiation of Col3a1+/- SMCs after stimulation with TGF-β1

Since SMCs migrated from arterial wall also play a critical role in neointimal formation, we also
examined phenotypes of SMCs in both Col3a1+/+and Col3a1+/- mice. Multiple experiments were
performed with SMCs explanted from both Col3a1+/+and Col3a1+/- aortas. As with fibroblasts, expression
of contractile markers was also detected. Results showed more dramatic increased messenger RNA
(Figure 4.9a) and protein accumulation (Figure 4.9b) of contractile markers in Col3a1+/- SMCs after
stimulation with TGF-β1 for 24 hours.

Figure 4.9 Increased expression of contractile proteins in Col3a1+/- myofibroblasts
RNA was isolated from both TGF-β1 treated and control SMCs cells at different time points. There
was increased messenger RNA expression of contractile proteins and accumulation of protein level in
both Col3a1+/- SMCs after TGF-β1 stimulation compared with control cells, but was more dramatic in
SMCs. qPCR was performed according to the protocol, p**<0.001, by the Student’s t-test.
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4.3.7

Altered focal adhesion by vinculin staining and increased differentiation of Col3a1+/- SMCs

Figure 4.10 Altered focal adhesion signaling in Col3a1+/- SMCs
Immunofluorescent staining (IF) to detect vinculin, marker for focal adhesions, results showed
that there was an alteration in distribution of focal adhesions in Col3a1+/- cells compared to that
in Col3a1+/+ with TGF-β1 treated for 48 hours.

102

Figure 4.11 Expression of collagens and collagen receptors at RNA level in SMCs
RNA was isolated from both TGF-β1 treated and control SMCs cells at different time points. There was
increased Col3a1 and Col1a1 expression after TGF-β1 stimulation compared with in Col3a1+/- SMCs.
And decreased of Itga2 and Itgb1 in Col3a1+/- SMCs qPCR was performed according to the protocol,
p**<0.001, by the Student’s t-test.

Whether the FAs in Col3a1+/- cells might be more mature compared to those from the Col3a1+/+ SMC
cells? To answer this question, IF of vinculin was conducted to show the size and location of focal
adhesions. Results showed an increase in vinculin intensity in Col3a1+/- SMCs visually (Figure 4.10),
indicating activation of FAK signaling and the maturation of FAs in the Col3a1+/- SMCs after TGF-β1
treatment.
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4.3.8

Altered production of collagen and their receptors Col3a1+/- SMCs
As with fibroblasts, expression of collagens, Col3a1, Col1a1 as well as collagen receptors Itga2,

Itgb1 was also detected. results showed a dramatic increase in expression of both Col3a1 and Col1a1 after
24 hours stimulation with TGF-β1 in both Col3a1+/- SMCs compared with Col3a1+/+ SMCs (Figure 4.11a),
a decreased expression of Itga2 and Itgb1 in Col3a1+/- SMCs compared with Col3a1+/+ SMCs after
stimulation with TGF-β1 for 24 hours (Figure 4.11b). Indicating a decreased integrin signaling
transduction in the Col3a1+/- SMCs.

Figure 4.12 Decreased cell proliferation while increased viability of Col3a1+/- SMCs
BrdU and MTT assay was performed according to assay protocols, and absorbance was
generated with plate reader at different wave length. There was decreased Col3a1+/- SMCs
proliferation compared to that of Col3a1+/+ SMCs (a) however, there was increased cell
viability in Col3a1+/- SMCs compared with Col3a1+/+ SMCs after stimulation with TGF-β1 for
24 hours (b). Statistical analysis: Student’s t-test, *p<0.05

4.3.9

Decreased cell proliferation and increased viability of Col3a1+/- SMCs
To determine the difference of SMCs in proliferation, BrdU assay and MTT assay on cells stimulated

with TGF-β1 for 24 hours (Figure 4.12a and b) were conducted. Data showed decreased Col3a1+/- SMCs
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proliferation compared to Col3a1+/+ SMCs. However, there was increased cell metabolic activity in
Col3a1+/- SMCs compared with Col3a1+/+ SMCs after stimulation with TGF-β1 for 24 hours. Indicating
their difference in cell metabolism (Figure 4.12 b).
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4.4

Discussion
Dysregulated function of myofibroblasts was shown from in vitro data by Dr. Amy Reid previously

(unpublished data from our lab). In her 3D fibrinogen culture model, there was increased contractile protein
expression as well as increased assembly of fibrillar collagens in the Col3a1+/- cells after induction with
TGF-β1. Results from Reid’s study and another study showing the differentiated Col3a1+/- fibroblasts
phenotype83 lead to the hypothesis that in the Col3a1+/- mouse model after carotid ligation, fibroblasts
might be showing a persistent differentiation status at the injury site due to the diminished content of type
III collagen resulting in delayed thrombus resolution and aberrant injury repair. To further elucidate the
phenotype of Col3a1+/- fibroblasts, we studied myofibroblast differentiation more closely.
Results showed that there was increased contractile protein expression at both RNA and protein level
the Col3a1+/- fibroblasts which was consistent with results from Amy’s study. The F/G actin assay showed
an increased proportion of F-actin polymerized in the Col3a1+/- cells after TGF-β1 treatment (Figure 4.5).
Under normal condition, fibroblasts will be activated and recruited to the injury site where they will be
differentiated into myofibroblasts by TGF-β186. TGF-β1 as a chemokine secreted mostly by platelet and
macrophages is critical for the entire process of wound healing87. Secretion of TGF-β1 at an early stage of
the healing prompts recruitment of inflammatory cells into the injury site, which are later involved in a
negative feedback via macrophages88. At the same time, TGF-β1 induced the expression of ECM
components like collagens by myofibroblasts. All these behaviors secure a successful wound healing after
injury. This is what we speculate to be happening in the Col3a1+/+ mice after carotid injury. In mice lung
tissues, this process is accompanied by the activation of pFAK signaling pathway followed the activation
of TGF-β1 and SMAD signaling pathway23. Therefore, we also looked at the size of the focal adhesions
(FAs) using IF staining of a representative FA marker, vinculin, as well as pFAk72,69. There was increased
vinculin area/cell area in Col3a1+/- cells compared to that in Col3a1+/+ at basal level, which indicated that
Col3a1+/- fibroblasts were more differentiated even when there was no stimulation with TGF-β1, which
was not shown by the data for the contractile proteins. But a dramatic increased vinculin area/cell area
(Indicating size of FAs) in Col3a1+/+ cells compared with that in Col3a1+/- cells after 72-hour TGF-β1
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induction. Also, there was significantly increased pFAK area/cell area in Col3a1+/+ cells compared with
that in Col3a1+/- cells at both basal level and after TGF-β1 treatment for 72 hours, indicating continuous
response of Col3a1+/+cells to drive expression of α-SMA to form stress fibers, as shown by IF data (Figure
4.6). When it was related to the in vivo situation, Col3a1+/+ myofibroblasts proliferate and produce normal
procollagen type III with help from TGF-β1 for the earlier wound healing phase and followed by producing
contractile proteins, especially α-SMA for a wound contracture and normal wound healing23. By contrast,
we hypothesize that in vivo in the Col3a1+/- mouse, although there is sufficient TGF-β1 secreted by the
persistent activated macrophages, the myofibroblasts are not producing enough procollagen type III. Thus,
although the cells are able to respond to TGF-β1 to stimulate pFAK and FA growth as well as initial
expression of contractile proteins (Figure 4.7), the FAs are linking up to aberrant collagen in the
extracellular matrix and they are unable to stimulate stress fiber formation to complete the differentiation.
Instead they activate MRTFA signaling pathway for F-actin formation and keep the producing α-SMA
(Figure 4.8). Even though, they are still not confident for contracture. We hypothesize that not only are
the cells failing to complete contracture due to the lack of collagen, but the myofibroblasts are failing to
undergo apoptosis and instead persistent differentiation and attempting to heal the wound long after the
process should be completed (Figure 4.13)
Due to the contribution of SMCs from arterial wall to the remodeling of arterial wall after injury 89,
we also investigated if there is any difference between SMCs from Col3a1+/+ and Col3a1+/- mice. Results
showed that Col3a1+/- SMCs present a more differentiated status by increasing expression of contractile
markers at both RNA and protein level compared with the Col3a1+/+ SMCs (Figure 4.9). Although there
was a decrease in Col3a1+/- SMCs proliferation, there was increased cell metabolic activity of Col3a1+/SMCs (Figure 4.12). Proliferation of SMCs is critical in intimal hyperplasia after arterial injury90. Results
from the SMC data showed that deficit of type III collagen impaired the neointima hyperplasia procedure
after arterial injury.
In conclusion, I was able to find consistently demonstrated that there was persistent myofibroblasts
differentiation status in the Col3a1+/- mice by the in vitro study. And study from the SMCs validate that
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the impaired arterial injury wound healing in the Col3a1+/- mice. In the future, studies should be focused
on whether any approaches could be applied to modulate the secretion of type III collagen in Col3a1+/fibroblasts, and then put the cells back to mouse model to correct their aberrant injury repair. Another
future study should be directed to more completely (mechanistically) link the collagen defect to the cellular
defects seen in the current study.

Figure 4.13 Proposed mechanisms for the persistent Col3a1+/- myofibroblasts status
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5

Discussion
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5.1

Discussion of the project
vEDS is the most severe type of EDS, with no effective therapeutic approach for patients. The widely

accepted dogma of vEDS pathogenesis is that defective production and a deficit of type III collagen leads
to a weakened arterial wall64. The deficit of collagen is mainly caused by the mutation at the Gly-X-Y site
of the type III collagen gene, Col3a1. Multiple studies suggest that arterial wall weakness and fragility are
the main causes of arterial aneurysm and dissection.
A review by Oderich el al. found 90 vEDS patients who showed bruised and translucent skin3,
indicating their aberrant injury repair ability. The focus of this dissertation research is to confirm how the
deficiency of type III collagen contributes to the pathogenesis of vEDS. Specifically, we explored the
mechanisms of aberrant arterial wound healing. We used a haploinsufficient Col3a1+/- mouse model, which
resembles vEDS patients by showing arterial and other phenotypes as seen in human patients 17.Previous
studies from our lab linked vEDS with dysfunctional fibroblasts in the Col3a1+/- mice. Additionally,
fibrocytes that are bone marrow-derived (BMD) differentiate into wound-healing myofibroblasts with the
expression of α-SMA27,48. Thus, we hypothesized that a bone marrow transplant (BMT) could correct the
ability of injury repair and alleviate the phenotypes in the Col3a1+/- mice after induced injury.
Previous studies from our lab have proposed a dis-regulated arterial wound healing process in the
Col3a1+/- mouse model. Our bone marrow transplant (BMT) data confirmed this finding. In the in vitro
study on fibroblasts, explanted Col3a1+/- mice validated our in vivo findings by showing a less mature
myofibroblasts phenotype.
The work presented in this dissertation showed the effectiveness of two potential approaches for
vEDS treatment, bone marrow transplantation and celiprolol trial, both of which improved post-injury
phenotypes in the Col3a1+/- mice.
Studies by Morissette et al. demonstrated that a chronic inflammation in vEDS patients91. They
detected markers of the TGF-β signaling pathways, using both patients’ plasma and dermal fibroblasts.
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According to the classification of vEDS severity and a correlation of phenotype-genotype as well as and
fat deposited in patients, they discovered an increased amount of TGF-β1, TGF-β2, MCP-1, CRP, ICAM1), VCAM-1 in vEDS patients. A higher mean platelet volume was also found in vEDS patients, which
suggested an increase in their platelet turnover result from persistent vascular damage, and adiposity65.
Results from the current study could be partially explained by persistent inflammation in vEDS patients.
In this current study, we also performed an ELISA assay on plasma to detect inflammatory factors in the
Col3a1+/- mice. We specifically detected ICAM1, VCAM-1 and MCP-1 at different time points, basal level,
POD3, POD7 and POD14. However, we were not able to show any conclusive findings from the ELISA
assays (Data not shown). Therefore, we cannot confirm increased circulating inflammatory factors in this
mouse model, and we cannot conclude that inflammation plays a role in the disease process.
Attention should be paid to our use of the painkiller drug ketoprofen which was administered to these
mice. There are multiples studies showed ketoprofen had anti-platelet activity of aspirin92,93. In contrast,
ibuprofen showed effects in inhibiting the platelet aggregation potency of aspirin compared with other
nonsteroidal anti-inflammatory drugs (NASIDs)94. Immediately after injury, platelets aggregation ensures
a normal thrombus formation and initiates successful wound healing 31; thus while ketoprofen might
promote the very early stage of wound healing, ibuprofen inhibits it. As a result of this early difference,
for future studies, attention should be paid to which painkiller drug to use and to interpret the results very
accurately.
The findings from the current study can also be applied to cerebrovascular diseases, which have been
manipulated by endovascular techniques95. But there have to be other techniques used at the same time to
minimize complications such as thromboembolic events, which is as high as 12.5%96. Platelets contribute
to both hemostasis and thrombosis95. Thromboembolic events also happen to people with acute coronary
diseases95. Although approaches for antiplatelet activity drugs have been applied, they can lead to either
ischemic or bleeding complications, respectively due to the different potency of the antiplatelet drugs and
their interactions97. For stroke happen to patients especially who are not older than 45 years, spontaneous
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dissection of brain vascular plays a huge role. Patients have vascular pathologies usually have experienced
trivial trauma, which resembles the carotid ligation we induced to Col3a1+/- mice98, through which a wound
healing process was initiated, persistent inflammation, not timely resolved thrombus leading to the medial
neovessel formation, finally predispose the rupture or dissection of the artery. And there was no optimal
medical treatment for cerebrovascular dissection. Currently, there are no data from clinical trials who has
confirmed antithrombotic with either anticoagulation or antiplatelet drugs98. To conclude, two big
problems in cerebrovascular disease are thrombosis and trauma, which are both relevant to the arterial
injury repair pathways described in this dissertation. The findings from this current study could therefore
be applied to those patients with cerebrovascular diseases, specifically, to reduce the inflammation and
decrease thrombosis by increasing resolution of thrombus after arterial injury.
On a broader scale, the therapies proposed in the current study can also be used to treat those diseases
which are characterized by defects in wound healing or disrupted scar formation, such as defective burn
wound healing, persistent burns with type II diabetes and fibrosis by modulating the hyperactivity of
fibroblasts/myofibroblasts21. Study by Duchesneau et al. showed that BMT could rescue function of lung
tissue using a cystic fibrosis (CF) model99, which is a fatal genetic disease resulting from mutation in CFTR
protein.. They found that transplant of wild type bone marrow into CFTR deleted recipient rescued the
phenotypes in CFTR-/- mice. Taken together, their results suggest that BMC can improve overall lung
function and may have potential therapeutic benefit for the treatment of CF. Thus, we further propose that
together with their studies, findings from the current study could be applied to multiple of other diseases.
However, there were still limitations to the current study. First, transgenic mouse model(s) with
specific Col3a1 mutation(s) are still not available, instead we used a haploinsufficient Col3a1 mouse
model. Although Col3a1-/- mice recapitulate syndromes of vEDS more closely, these mice rarely survive
after birth. Col3a1+/- mice have a milder phenotype100. Second, although BMT rescued the phenotypes
showed in the Col3a1+/- mice, we were not able to examine or exclude the immune responses after BMT.
Third, there might be some technique limitations of the BMT procedure. Since we transplanted the whole
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bone marrow cells into each recipient mouse without isolating specific a fibrocyte population, even though
we speculate that BMD fibrocytes are involved in wound healing, we cannot whether it was possible for
there to be other cells like macrophage or other BMD cells actually participating in rescuing the phenotypes.
There is therefore still a lot of work to be done before a clinical study on vEDS patients could be initiated.
The mouse model used for this current project provides a basic idea which will direct future studies
on vEDS patients with severe mutations and their roles in the disease. It also provides a strong early data
which links mechanisms of vEDS patients and the role of decreased production of type III collagen. Most
importantly, the current work provides us with two potential therapeutic approaches for this deadly disease.
In the long run, we expect that these studies will be applied to clinical use after further work solving the
above stated limitations.

5.2
5.2.1

Future direction
In vitro studies on Col3a1+/+ and Col3a1+/- fibroblasts to test their metabolism and cell
interaction
The in vitro data from chapter 4 showed increased MTT incorporation in Col3a1+/- fibroblasts; it could

be possibly explained by the changes in cell metabolism, which is regulated mainly by the mammalian
target of rapamycin (mTOR) signaling101. We will look at differences in mTOR signaling between
Col3a1+/- and Col3a1+/+ fibroblasts, and will do further studies to mechanistically link these signaling
changes with adhesion-based pathways.

5.2.2

Investigating the role of specific bone marrow derived cell types in Col3a1+/- mouse model
There are multiple different functions of macrophages in wound healing, including host defense, the

inflammatory responses, cell apoptosis and tissue restoration46. Specifically, first, it would be of great
interest to isolate fibrocytes, macrophages and fibroblasts from Col3a1+/- and Col3a1+/+ mice by flow
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cytometry with their differentiated cell surface markers102,103. We could use these cells in vitro to study any
changes in phenotype and any interaction between these cell types. We expect macrophage phenotype not
to be affected and fibrocyte phenotype to be similar to the reported findings in Chapter 4 for lung
fibroblasts. Finally, after in vitro culture of isolated fibrocytes, both Col3a1+/+ and Col3a1+/fibroblasts/macrophages would be injected into both two groups of mice respectively, and then compare if
there is any correction in the injury repair ability of Col3a1+/- mice by using the carotid ligation injury
model.

5.2.3

Specialized cell therapy for vEDS.
In developmental biology and cancer biology as well as vascular biology, cell therapy has been widely

studied and accepted as an effective approach for a variety of diseases104. It is of great interest for us to try
similar method for vEDS patients. First, gene cloning technique should be used to establish the stable
protein expression system of procollagen type III. Then the system could be induced into immortalized
fibroblasts/myofibroblasts, followed by injecting the cells into both Col3a1+/+ and Col3a1+/- mice, to check
if there is increased injury repair ability of Col3a1+/- mice by same mouse model.

5.2.4

Effects of celiprolol on cells explanted from Col3a1 mouse.

One last, but not least future study is highly proposed to investigate the role of celiprolol using in vitro
tissue cultured fibroblasts or even macrophages. Phenotypes such as cell migration, proliferation and the
secretion of inflammatory factors as well as neo-angiogenesis of these cells should be examined on both
Col3a1+/+ and Col3a1+/- cells. This study is of great importance to illustrate the mechanisms underlie how
celiprolol could decrease the severity of vEDS and how celiprolol could be best applied for vEDS patients.
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